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ABSTRACT 
METAVACCINOLOGY: A NEW VACCINE DISCOVERY TOOL 
 
Emrah Altındiş 
 
 
Dr. Sabrina Liberatori 
Prof. Dr. Vincenzo Scarlato 
March 2011, 162  pages 
 
In the last decade, the reverse vaccinology approach shifted the paradigm of vaccine 
discovery from conventional culture-based methods to high-throughput genome-based 
approaches for the development of recombinant protein-based vaccines against pathogenic 
bacteria.  Besides reaching its main goal of identifying new vaccine candidates, this new 
procedure produced also a huge amount of molecular knowledge related to them. In the 
present work, we explored this knowledge in a species-independent way and we performed a 
systematic in silico molecular analysis of more than 100 protective antigens, looking at their 
sequence similarity, domain composition and protein architecture in order to identify possible 
common molecular features. This meta-analysis revealed that, beside a low sequence 
similarity, most of the known bacterial protective antigens shared structural/functional Pfam 
domains as well as specific protein architectures. Based on this, we formulated the hypothesis 
that the occurrence of these molecular signatures can be predictive of possible protective 
properties of other proteins in different bacterial species. We tested this hypothesis in 
Streptococcus agalactiae and identified four new protective antigens. Moreover, in order to 
provide a second proof of the concept for our approach, we used Staphyloccus aureus as a 
  
v
second pathogen and identified five new protective antigens. This new knowledge-driven 
selection process, named MetaVaccinology, represents the first in silico vaccine discovery 
tool based on conserved and predictive molecular and structural features of bacterial 
protective antigens and not dependent upon the prediction of their sub-cellular localization. 
Key words: MetaVaccinology, Streptoccus agalactiae, Staphylococcus aureus, 
5’nucleotidases, vaccinology, genomics, proteomics 
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1. INTRODUCTION 
1. 1 Brief History of Vaccinology 
In the beliefs of ancient peoples, diseases were inflicted on mankind by intangible and 
capricious deities as punishment for ill-defined transgressions. Fear of destruction by disease 
became an effective tool used by rulers and politicians to instill terrors, which would prove 
useful in controlling human behavior in the long climb from early tribal to “civilized” 
existence.  However, some, who were the forerunner of modern science, did discover 
microbial life forms, the relationships of environment to disease, and the fact that there was 
no second occurrence following certain clinically definable illnesses. Such heretical concepts 
revealed that man himself, rather than devils and demons, were the source of pestilence (1). 
It was common knowledge that survivors of smallpox became immune to the disease. The 
most successful way of combating smallpox before the discovery of vaccination was 
inoculation. The word is derived from the Latin inoculare, meaning “to graft.” Inoculation 
referred to the subcutaneous instillation of smallpox virus into nonimmune individuals.  In 
1670, Circassian traders introduced variolation to the Turkish “Ottoman” Empire. Variolation 
came to Europe at the beginning of the 18th 
century with the arrival of travelers from Istanbul. It was the continued advocacy of the 
English aristocrat Lady Mary Wortley Montague that was responsible for the introduction of 
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variolation in England. In 1717, Lady Montague’s husband, Edward Wortley Montague, was 
appointed ambassador to the Sublime Porte. A few weeks after their arrival in Istanbul, Lady 
Montague wrote to her friend about the method of variolation used at the Ottoman court. Lady 
Montague was so determined to prevent the ravages of smallpox that she ordered the embassy 
surgeon, Charles Maitland, to inoculate her 5-year-old son. The inoculation procedure was 
performed in March 1718. Upon their return to London in April 1721, Lady Montague had 
Charles Maitland inoculate her 4-year-old daughter in the presence of physicians of the royal 
court. After these first professional variolation procedures, word of the practice spread to 
several members of the royal family (2).  
 
 
Figure 1: The first smallpox vaccination. Smallpox is stemmed (3). 
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The modern science of vaccinology took off on 14 May 1796 when Edward Jenner inoculated 
James Phipps, with the vaccinia virus obtained from a young woman who had been 
accidentally infected by a cow. Jenner describes this key experiment with the following 
words:  
 “The more accurately to observe the progress of the infection, I selected a healthy boy about 
eight years old for the purpose of inoculation with the cowpox. The matter was taken from the 
suppurated sore on the hand of a dairy Maid who was infected by her master’s Cows, and it 
was inserted on the 14th May 1796 into the arms of the Boy by means of two superficial 
incisions each about three quarters of an inch long. .During the whole of [the ninth day after 
this] he was perceptibly indisposed and had a restless night; but, on the following day he was 
perfectly well. On the 1st of July following this, the Boy was inoculated with Matter 
immediately taken from a smallpox Pustule. Several punctures and slight incisions were made 
in both his arms, and the matter was well rubbed into them, but no disease followed (4). 
The history of modern vaccination as a deliberate endeavor began in the laboratory of Louis 
Pasteur. His aphorism that 'chance favors the prepared mind' was never more aptly 
illustrated than by his own discovery of attenuation. Pasteur was on vacation in the summer of 
1881, and returned in the autumn to studies of chicken cholera, caused by what we call today 
Pasteurella multocida. A culture left on the bench during the summer was inoculated into 
chickens but did not cause disease. Pasteur then made a fresh culture and inoculated the same 
chickens, whether through parsimony or purpose we do not know. In any case, the chickens 
were resistant to the fresh challenge, and Pasteur realized that the aged culture had rendered 
them immune. From these observations Pasteur constructed the hypothesis that pathogens 
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could be attenuated by exposure to environmental insults such as high temperature, oxygen 
and chemicals. His ensuing work on anthrax and rabies confirmed the hypothesis. In the next 
century, Calmette and Guérin used passage in artificial media to attenuate Mycobacterium 
bovis, and Theiler used passage in mice and chick embryos to attenuate yellow fever virus (5). 
 
Figure 2: Two important figures of modern vaccionology: Robert Koch and Louis 
Pasteur. 
 
That was apparent during the first era of modern vaccinology, from the late nineteenth century 
through the 1930s: a long era of grand expectations. From the point of the 1890s, there was 
every reason to believe that a remarkable series of vaccine innovations would follow the 
scientific breakthroughs of Robert Koch, Louis Pasteur, and others. For the first time in 
human history, the sources of disease could be analyzed in a systematic, scientific manner. 
Thanks to Pasteur, society now had a vaccine effective against rabies, and other scientists 
followed with killed-organism vaccines for protection against cholera, typhoid, and plague. 
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Armed with a better understanding of immunology and with a new serum antitoxin that was 
effective against diphtheria, leading scientists and physicians at the turn of the century can be 
excused their sense of vigorous optimism. After all, they were not along in their hubris many 
prominent political leaders, pundits, and tycoons joined them in expressing wild expectations 
about progress in the years ahead.  There were as well experimental vaccines, not all of which 
were effective and safe, against diphtheria, pertussis, tuberculosis (BCG), tetanus, yellow 
fever, and typhus (Rickettsia ) (6). 
After the applications of killed and attenuated vaccines, the vaccine revolution continued to 
progress by the invention of cell culture, recombinant vaccines and polysaccharide 
technology. Today, iimmunization is a proven tool for controlling and even eradicating 
diseases. Table 1 shows the list of the approved vaccines yet. An immunization campaign 
carried out by the World Health Organization (WHO) from 1967 to 1977 eradicated the 
natural occurrence of smallpox. When the programme began, the disease still threatened 60% 
of the world's population and killed every fourth victim. Eradication of poliomyelitis is within 
reach. Since the launch by WHO and its partners of the Global Polio Eradication Initiative in 
1988, infections have fallen by 99%, and some five million people have escaped paralysis. 
Between 1999 and 2003, measles deaths dropped worldwide by almost 40%, and some 
regions have set a target of eliminating the disease. Maternal and neonatal tetanus will soon 
be eliminated in 14 of 57 high-risk countries (7).  In the next chapter, we will go on with the 
influence of genomics revolution to vaccine development. 
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Table 1. Dates of introduction of commonly used vaccines (8) 
 Vaccine Date  Vaccine Date 
1 Smallpox 1796 22 Pneumococcus 1976 
2 Rabies 1885 23 Acellular P (Pa) 1981 
3 Cholera 1896 24 Hepatitis B (HB) 1981 
4 Typhoid 1896 25 Varicella (V) 1984 
5 Plague 1896 26 rDNA HB 1986 
6 Diphtheria (D) 1923 27 H. influenzae b (Hib) 1988 
7 Pertussis (Pw) 1926 28 Hepatitis A (HA) 1991 
8 Tetanus (T) 1927 29 DTPwIPVHib 1993 
9 Tuberculosis (BCG) 1927 30 DTPa 1994 
10 Yellow fever 1935 31 DTPwHB 1996 
11 Influenza 1936 32 HBHA 1996 
12 Polio (IPV) 1955 33 DTPaHib 1997 
13 DTPw 1957 34 DTPaIPVHib 1997 
14 Polio (OPV) 1958 35 Lyme 1998 
15 DTIPV 1961 36 Rotavirus 1998 
16 Measles (M) 1963 37 Dtpa 1999 
17 DTPIPV 1966 38 HATy 1999 
18 Mumps (M) 1967 39 DTPaHBIPV 2000 
19 Rubella (R) 1969 40 DTPaHBIPVHib 2000 
20 MMR 1971 41 
MCCVb  (MenC conjugate 
vaccine) 2000 
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21 Meningococcus 1972 42 PCVa(conjugate vaccine) 2000 
 
1.2 A new generation: Subunit Vaccines 
After attenuated and killed type of vaccines, a new generation introduced as vaccines against 
diphtheria and tetanus in the 1920s is a much more sophisticated product, a purified bacterial 
component. In both these cases, it is a protein toxin previously demonstrated to be an essential 
cause of the disease. For the vaccine, the toxin is chemically modified to yield the non-toxic 
toxoid. Both these vaccines have performed extremely well in terms of both safety and 
efficacy, demonstrating that the theory behind them was correct. Purified single component 
vaccines have many attractions: the immune stimulus is maximally directed to the molecule 
relevant for protection and additional components that could cause adverse reactions or other, 
unwanted but unknown problems are avoided (9).  
This significant knowledge, that a protein and/or a subunit of a pathogen is enough to 
stimulate a specific immune response then used in order to make vaccines against pathogens 
that cannot be grown or can be grown only with difficulty in vitro pose a special problem to 
vaccine development.  Molecular biology and genetic engineering have had a dramatic effect 
on the field of vaccinology, although many of the important advances have not yet made it 
into the market. The first success story in this area was the development of the hepatitis B 
vaccine, which was licensed in 1986. The surface protein of hepatitis B virus is expressed 
from a DNA plasmid in yeast cells, purified and adsorbed on alum for injection (10). 
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As with diphtheria, the new generation of vaccines against pertussis (whooping cough) was 
made from a toxin that had been deactivated with formaldehyde. Rino Rappuoli and his 
colleagues achieved to make this subunit vaccine against Bordetella pertussis, the etiologic 
agent of whooping cough. Dr. Rappuoli describes this process as: “I cloned and sequenced the 
gene for pertussis toxin and did what Pappenheimer had done 15 years before with 
diphtheria” (11). But this time they used site-directed mutagenesis to specifically alter amino 
acids in the active site of the toxin. The result was a nontoxic molecule that made a potent 
vaccine. The pertussis vaccine also established a new generation of so-called acellular 
vaccines, which, unlike older vaccines, did not contain cells or cell fragments (12). 
Both of Hepatitis B and acellular pertussis vaccines are widely used in all over the world.  
Hepatitis B vaccine is 95% effective in preventing HBV infection and its chronic 
consequences, and is the first vaccine against a major human cancer. The vaccine has an 
outstanding record of safety and effectiveness. Over one billion doses of hepatitis B vaccine 
have been used worldwide. In many countries where 8% to 15% of children used to become 
chronically infected with HBV, vaccination has reduced the rate of chronic infection to less 
than 1% among immunized children (13).  
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1.3 Genomics and Vaccinology 
Louis Pasteur, who developed the first vaccine against rabies, established in 1881 the basic 
paradigm for vaccine development, which included the isolation, inactivation and injection of 
the causative microorganism. These basic principles have guided vaccine development during 
the twentieth century. All existing vaccines are based on killed or live-attenuated 
microorganisms or subunits purified from the microorganism such as toxins detoxified by 
chemical treatment, purified antigens or polysaccharide conjugated to proteins (Table 1). 
Vaccines produced following Pasteur’s principles allowed the control and, in some cases, the 
eradication of many important infectious diseases. Despite several successes, the Pasteur’s 
approach to vaccine development took a long time to generate vaccines against those 
pathogens for which the solution was feasible, but failed to produce vaccines for those 
bacteria and parasites that do not have obvious immunodominant protective antigens or for as 
yet uncultivable microorganisms (14). The genome era has completely changed the way to 
design vaccines. The availability of the complete genome of microorganisms combined with a 
novel advanced technology has introduced a new prospective in vaccine research. It is now 
possible to determine the complete genome sequence of a bacterial pathogen in a very few 
months at very low cost. In 1995, The Institute for Genomic Research (TIGR) published the 
first microbial complete genome sequence of Haemophilus influenzae (15). As of December 
2010, 1,283 bacterial genomes are completely sequence and more than 5433 are ongoing 
(http://www.genomesonline.org/cgi-bin/GOLD/bin/gold.cgi). 
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Figure 3. Schematic overview of conventional vaccinology versus vaccinology in the 
genome era. (A) Most licensed vaccines target pathogens that have low antigenic variability 
and pathogens for which protection depends on antibody-mediated immunity. These vaccines 
have typically been developed using conventional vaccinology. (B) Several pathogens are 
shown for which no vaccine is available, due to either their high antigenic variability and/or 
the need to induce T cell–dependent immunity to elicit protection. New approaches are being 
applied to vaccine development for these pathogens in the genome era. Vaccines/diseases 
shown in the figure are selected examples of each category and are not a complete list (16). 
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The application of genome analysis to vaccine development, a concept termed “reverse 
vaccinology,” initiated a positive feedback loop in terms of the development and application 
of novel approaches to the field of vaccinology. As a result, it is becoming possible to 
systematically examine almost every aspect of a pathogen and its interactions with the host 
immune system in the search for vaccine candidates. Reverse vaccinology applied to the 
genome of a pathogen aims to identify the complete repertoire of antigens that an organism is 
capable of expressing on its surface. Transcriptomics and proteomics enable the investigation 
of the array of antigens actually expressed by a pathogen under specified conditions, by 
examining the mRNA and protein of the organism, respectively. Analysis can also focus on 
the subset of proteins that are surface exposed (surface proteome) or the subset of genes that 
are functionally important for infection (functional genomics). Newer fields of study are 
focused on elucidating the set of antigens that interact with the host immune system and the 
mechanisms involved in these interactions (immunomics), the structural epitopes of 
immunogenic antigens (structural vaccinology), and the way in which individual host immune 
systems respond to a vaccine (vaccinomics) (16). While each of these approaches has 
limitations, they have all emerged as powerful tools in vaccine development.  
The approach referred to as ‘reverse vaccinology’ uses the genome sequences of viral, 
bacterial or parasitic pathogens of interest rather than the cells as starting material for the 
identification of novel antigens, whose activity should be subsequently confirmed by 
experimental biology. In general, the aim is the identification of genes potentially encoding 
pathogenicity factors and secreted or membrane-associated proteins. Specific algorithms 
suitable for the in silico identification of novel surface-exposed and, thus, antibody 
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accessible proteins mediating a protective response are used (17). The first example of a 
successful application of the reverse vaccinology approach was provided by Pizza and 
coworkers in collaboration with The Institute for Genomic Research. 
 
Figure 4: Examples of different post genomics approaches in the development of 
vaccines against some bacterial pathogens, and the status of the corresponding vaccine 
development (18) 
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1.3.1 The first Steps of Reverse Vaccinology 
Neisseria meningitidis is a major cause of meningitis and sepsis in children and young adults. 
While polysaccharidebased vaccines are available for A, C, Y and W135 serogroups, 
conventional vaccinology has failed for serogroup B. Group B meningococcus (MenB) 
represents the first example to which reverse vaccinology has been applied. MenB complete 
genome from strain MC58 was obtained by the random shotgun strategy (19). While the 
sequencing was still in progress, the MenB genome was screened, using several softwares, in 
order to select putative ORF coding for surface-exposed or secreted proteins. Among the 2158 
putative open reading frames (ORFs) annotated, 600 ORFs were selected on the basis of these 
criteria. The selected 600 ORFs were amplified from meningococcus by PCR, and cloned into 
Escherichia coli in order to express each gene as His-tag or GST fusion protein. Out of these 
600 putative ORFs, 350 were successfully expressed, purified and used to immunize mice. 
Screening of immune sera was performed by Western blot on meningococcus total cell lysates 
and outer membrane vesicles to verify whether the protein was really expressed in 
meningococcus and to determine its subcellular localization. The surface-exposure of each 
antigen was then confirmed by fluorensce-activated cell sorter (FACS) analysis and ELISA 
on whole cell bacteria. Finally, sera were tested in bactericidal assay, an assay which is 
known to correlate with the protection in humans. Ninety-one proteins were found to be 
surface-exposed, 29 of them were able to induce bactericidal antibodies (20).  
These 29 antigens selected by reverse vaccinology were prioritized based on their ability to 
induce broad protection. The three top antigens that met the prioritization criteria were 
GNA2132, GNA1870, and NadA. Two additional antigens, GNA1030 and GNA2091, were 
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selected because they also induced protective immunity but only in some of the assays. The 
results of the multicomponent vaccine were very promising, the vaccine covers 78% of the 
strains in the basic formulation using aluminum hydroxide as adjuvant, and coverage can be 
increased to 95% of the strains by using other adjuvants. The progress compared with 
vaccines available so far is gigantic; in fact, OMV vaccines, which are the best vaccines 
against MenB developed during the last 30 years, are shown to cover only 20% of the MenB 
strains (21). This work also shows that universal protein-based vaccines can be developed 
against those encapsulated bacteria that are usually targeted by conjugate vaccines.  
 
Figure 5.  Flow chart showing criteria and bioinformatic softwares for the in silico 
genome analysis and selection of putative vaccine candidates (15). 
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1.3.2 Pan-Genome and Reverse Vaccinology  
Tettelin et al. introduced the concept of pan-genome, which was defined as the global gene 
repertoire pertaining to a given species (22). The pan-genome can be defined as the global 
gene repertoire pertaining to a species. In general, it can be divided in three parts: the core-
genome, which includes the set of genes invariably present and conserved in all the isolates; 
the ‘dispensable genome’, comprising genes present in some but not all the strains, and the 
strain-specific genes, which are present only in one single isolate. The analysis performed on 
GBS genomes indicated that the different isolates have an estimated core-genome containing 
1806 genes, whereas each single genome contained between 2000 and 2400 genes. In other 
words, each strain contains a relatively large number of dispensable genes (200–600) that are 
missing in at least one of the other strain genomes. The most interesting finding is that when a 
new genome sequence is added to the pool of the others, an estimated number of 33 new 
strain specific genes, which are exclusively present in that genome, are added. Consequently, 
the pool of genes comprising the coregenome, dispensable genome and all the strain-specific 
genes, globally defined as the pan-genome, represents an open entity (open pan-genome) that 
is continuously increasing in size (24). 
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Figure 6. The pan-genome. The number of specific genes is plotted as a function of the 
number n of strains sequentially added. For GBS (blue line), the extrapolated average number 
of strain-specific genes, 33, is shown as a dashed line. For Bacillus anthracis (red line), the 
curve reaches zero after addition of the fourth genome. No new genes will be discovered after 
this threshold (24). 
Besides the study of the diversity inside a species, one possible application of the pan-genome 
in vaccinology (pan-genomic reverse vaccinology) is the identification of novel vaccine 
candidates and targets for antimicrobials. Maione and colleagues performed the first 
application of the pan-genome to vaccines to design a universal vaccine against GBS (25). By 
computational algorithms 589 surface-associated proteins are predicted, 396 of which were 
  
17
core genes and those remaining were genes absent in at least one strain. Selected potential 
antigens were expressed as recombinant proteins, purified and tested for protection against 
GBS, and four were found to elicit protective immunity in an animal model. Among these 
antigens, only one was part of the core genome; however, it was not able to confer global 
protection, hence the final vaccine formulation should include a combination of the four 
antigens (25). The GBS example has demonstrated that multiple genome sequences of each 
species are important to cover the diversity of many pathogens  
1.3.3 Substractive Reverse Vaccinology for Escherichia coli 
The most recent paper of Reverse Vaccinology is published on extraintestinal pathogenic 
Escherichia coli (ExPEC) which is a common cause of disease in both mammals and birds. 
Moriel et al. have determined the genome sequence of ExPEC IHE3034 (ST95) isolated from 
a case of neonatal meningitis and compared this to available genome sequences of other 
ExPEC strains and a few nonpathogenic E. coli. To identify potential vaccine candidates 
against ExPEC, they applied a “subtractive reverse vaccinology” approach. Briefly, antigens 
predicted to be surface associated or secreted and with no more than three transmembrane 
domains were selected by bioinformatic analysis of the IHE3034, 536, and CFT073 genomes. 
The presence (and the level of similarity) of these antigens in the nonpathogenic strains 
MG1655, DH10B, and W3110 were used as exclusion criteria. By this approach, they were 
able to identify 230 potential antigens, which were then expressed as His-tagged proteins, 
purified and tested for protection in a sepsis mouse model. Of these, 220 were successfully 
purified, 69 as soluble and 151 as insoluble proteins. Nine antigens were protective in a 
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mouse challenge model. Some of them were also present in other pathogenic non-ExPEC 
strains, suggesting that a broadly protective E. coli vaccine may be possible (26). 
1.3.4 ANTIGENome Technology 
In 2000, Etz et al published the first article of  ANTIGENome technology. They developed a 
new procedure to identify commonly recognized antigens, and provide a comprehensive in 
vivo antigenic profile of Staphylococcus aureus. Very briefly, S. aureus peptides were 
displayed on the surface of Escherichia coli via fusion to one of two outer membrane proteins 
(LamB and FhuA) and probed with sera selected for high Ab titer and opsonic activity. A total 
of 60 antigenic proteins were identified, most of which are located or predicted to be located 
on the surface of the bacterium or secreted. The authors claim that the identification of these 
antigens and their reactivity with individual sera from patients and healthy individuals could 
facilitate the selection of promising vaccine candidates for further evaluation.(27). The 
authors argue that the ANTIGENome technology does not directly rely on genome annotation 
and, thus, has the potential to select proteins that are not predicted by ORF-finding algorithms 
(28). 
ANTIGENome approach was secondly applied to Streptococcus pneumoniae by using display 
libraries expressing 15–150 amino acid fragments of the pathogen’s proteome. Serum 
antibodies of exposed, but not infected, individuals and convalescing patients identified the 
ANTIGENome of pneumococcus consisting of 140 antigens, many of them surface exposed. 
Based on several in vitro assays, 18 novel candidates were preselected for animal studies, and 
4 of them showed significant protection against lethal sepsis.. A vaccine containing two of 
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four protective antigens, PcsB and StkP, is planned for the prevention of infections caused by 
all serotypes of pneumococcus in the elderly and in children (29). 
Very recently, the same group published their ANTIGENome approach for Streptococcus 
pyogenes. For immune selection, human serum antibodies obtained from patients who 
recovered from common S. pyogenes infections and healthy, noncolonized parents of small 
children, were used. These studies led to the discovery of eight novel antigens in addition to 
Spy0416/ScpC, all of which are highly conserved among GAS clinical isolates and provide 
significant protection in murine challenge models (30). 
1.4 Proteomics and Vaccinology 
The term proteome, in analogy to the term genome, was coined to describe the complete set of 
proteins that an organism has produced under a defined set of conditions. The genome is static 
since it represents the blueprint for all cellular properties that a cell is able to develop. In 
contrast, the proteome is highly dynamic and much more complex than the genome. It is 
critical for survival that the protein composition of a cell is constantly adjusted to meet the 
challenges of changing environmental conditions (31). Already in 1975, the powerful method 
of two-dimensional-polyacrylamide gel electrophoresis (2D PAGE) was introduced that 
allowed one to separate highly complex cellular protein extracts into individual proteins on a 
single gel based on two properties of the proteins the isoelectric point (pI) and the molecular 
weight (MW) (32). Based on a well-annotated genomic sequence, it became possible to 
introduce large-scale mass spectrometry (MS) techniques to identify virtually every protein 
detected on a 2D gel. The increase in throughput, the partial automation, and the higher 
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reproducibility of 2D-PAGE analysis recently made it a very attractive tool to study cellular 
functions on a molecular level. 
Proteomics approaches to pathogens may have different targets: (i) Characterization of 
submicrobial proteomes (for example, secreted proteins, surface proteins and immunogenic 
proteins), (ii) comparative analysis of different strains and physiological states, (iii) 
identification of proteins related to pathogenicity, (iv) identification of proteins involved in 
host–pathogen interactions and (v) evaluation of mechanisms of action of antimicrobials are 
the most important ones (33). Proteomic approaches to vaccine candidate selection are able to 
go beyond several limitations of bioinformatics tools, which rely on homology searches, in 
predicting whether or not a protein is surface-exposed (34). 
 
Figure 6. The mass-spectrometry/proteomic experiment.  A protein population is prepared 
from a biological source — for example, a cell culture — and the last step in protein 
purification is often SDS–PAGE. The gel lane that is obtained is cut into several slices, which 
are then in-gel digested. The generated peptide mixture is separated on- or off-line using 
single or multiple dimensions of peptide separation. Peptides are then ionized by electrospray 
ionization (depicted) or matrix-assisted laser desorption/ionization (MALDI) and can be 
analysed by various different mass spectrometers. Finally, the peptide-sequencing data that 
are obtained from the mass spectra are searched against protein databases using one of a 
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number of database-searching programmes (2D, two-dimensional; FTICR, Fourier-transform 
ion cyclotron resonance; HPLC, high-performance liquid chromatography) (35). 
1.4.1 Immunoproteomics 
Much of information about immunogenic components of a bacterial pathogen can be derived 
from proteomics coupled to Western blotting, namely immunoproteomics. The aim of the 
immunoproteomics studies is to identify the immunogenic antigens of a pathogen by using 
sera of human or mice.  Immunproteomics has been used to identify novel bacterial vaccine 
candidates against several human pathogens, examples including Helicobacter pylori, 
Staphylococcus aureus, Bacillus anthracis, Shigella flexneri, Francisella tularensis, 
Corynebacterium diphtheriae, Streptococcus pyogenes, Chlamydia pneumoniae, Neisseria 
meningitidis and Bordetella pertussis (36).  
During my master thesis (2004-2007, Middle East Technical University, Ankara), I had used 
immunoproteomics in order to study B. pertussis, the causative agent of highly communicable 
respiratory infection whooping cough (http://etd.lib.metu.edu.tr/upload/12608320/index.pdf ). 
In a few words, the total soluble proteins extracted from two B. pertussis strains, Tohama I 
and the local isolate Saadet, two strains used for vaccine production in Turkey, were separated 
by two-dimensional gel electrophoresis and analyzed by Western blotting for their reactivity 
with the antisera obtained from the mice immunized with inactivated whole cells as well as 
those collected from the mice challenged intraperitoneally with live cells of each strain. Of a 
total of 25 immunogenic proteins identified, in which 21 were shown to be the novel antigens 
for B. pertussis. This was the first immunoproteomics study of the Bordetella and has 
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provided us a deeper idea about the pathogen.  
 
Figure 7: Impact of proteomics on vaccine development (37) 
1.4.2 Surfome Analysis as a Vaccine Discovery Tool 
Bacterial surface proteins are essential compartments of the pathogens. They have 
fundamental roles in interaction with the host and environment hence they are the main 
virulence factors that involve in adhesion and invasion of the host cells. Moreover, because 
surface proteins are likely to interact with the host immune system, they may become 
components of effective vaccines. There are three main methods currently in practice to 
identify surface proteins: (i) prediction by genome analysis using algorithms such as PSORT, 
(ii) separation of membrane and cell wall fractions from the cytoplasmic fraction and then 
  
23
identification of proteins by two-dimensional (2D)-electrophoresis or 2D-chromatography 
coupled to mass spectrometry and (iii) definition of membrane proteins by using one of the 
two methods described above and then confirmation of surface localization by producing 
polyclonal antibodies against the recombinant forms of each predicted protein and by 
assaying antibody binding to whole bacterial cells. All these methods are used widely but they 
are all extremely labor intensive and/or not fully reliable and is not quantitative (38).  
 
Figure 8. Structures of surface-exposed and secreted proteins relevant to the 
pathogen–host interface. Represented examples can be specific or common to different 
pathogen classes. The following indicates the antigen's name, pathogen's species and PDB 
codes, respectively, for each structure drawn: (a) OmpF, Escherichia coli, 1gfn; (b) YadA, 
Yersinia pestis, 1p9h; (c) PapG, Escherichia coli, 1j8s; (d) PapE-PapK, Escherichia coli, 
1n12; (e) Psv25, Plasmodium vivax, 1z27; (f) EBA127, Plasmodium falciparum, 1zrl; (g) 
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AMA-1, Plasmodium vivax, 1w8k; (h) BoNT-B, Clostridium botulinum, 1epw; (i) InlA, 
Lysteria monocytogenes, 1O6T; (j) SdrG, Staphylococcus epidermidis, 1r19; (k) SpnHl, 
Streptococcus pneumoniae, 1egu. (39) 
Recently, Rodriguez-Ortega et al. from Novartis Vaccines,  described a new approach that 
allows the rapid and selective identification of bacterial surface-exposed proteins, the pool of 
proteins which are entirely or partially exposed on the outside of bacterial cells. The method 
uses proteolytic enzymes to ‘shave’ the bacterial surface and the peptides generated are 
separated from the whole cells and identified by mass spectrometry. The approach described 
provided the most extensive and detailed map of the surface-exposed antigens of a GAS 
isolate to date. A relevant result of this work was the demonstration that comprehensive 
characterization of surface-exposed proteins can lead to new vaccine candidate discovery. 
Among the 14 identified surface proteins tested, one protein, Spy0416, conferred high 
protection levels. This was a remarkable result, considering the small number of protective 
antigens that have been identified to date (38).  
Secondly, our group used this approach in order to analyze the surfome of Group B 
Streptococcus, COH1 strain and to identify new vaccine candidates.  We confirmed previous 
data showing that whole viable bacterial cell treatment with proteases followed by the 
identification of released peptides by mass spectrometry is the method of choice for the rapid 
and reliable identification of vaccine candidates in Gram-positive bacteria. When applied to 
the Group B Streptococcus COH1 strain, 43 surface-associated proteins were identified, 
including all the protective antigens described in the literature as well as a new protective 
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antigen, the cell wall-anchored protein SAN_1485 belonging to the serine-rich repeat protein 
family (40).  
In the present study, the surface digestion methodology was exploited in order to analyze 
expression of new protective antigens on the surfome of GBS. 
 
Figure 9. Representation of the proteomics strategy used to identify surface-exposed 
proteins (40). 
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1.5 Protein Domains 
Traditionally, scientists use sequence similarity searches to compare a query sequence to 
those of known function, but this method has its limitations and relies on the quality of 
existing data. Alternative methods for protein sequence classification use protein signatures. 
A number of different databases developing protein signatures diagnostic for known protein 
families or domains have arisen (41). 
Protein domains are compact regions of a protein’s structure that often convey some distinct 
function. Domain architecture, or order of domains in a protein, is frequently considered as a 
fundamental level of protein functional complexity. The prevalence of proteins with more 
than two domains and the recurrent appearance of the same domain in non-homologues 
proteins show that functional domains are reused when creating new proteins. Because of this, 
domains have been likened to Lego bricks that can be recombined in various ways to build 
proteins with completely new functions. Hence, one way to study evolution of protein 
function and structure is by looking at the evolution of protein domain composition. The 
average length of a protein domain is approx. 120 amino acids, so changes in domain 
architecture are underlined by large alterations at the gene level (42). Examples of molecular 
mechanisms that can direct these rearrangements are gene fusion and fission, exon shuffling 
through intronic recombination, alternative gene splicing and retropositioning  
Ernest Rutherford, who is known as the father of nuclear physics famously and 
contemptuously said, ‘All science is either physics or stamp collecting’. But ‘stamp 
collecting’ or classification is of central importance in science. The advent of high 
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throughput sequencing and bioinformatics has enabled the classification of the proteins 
through the identification of sequences similarities they contain. These similarities are often 
characteristic of shared protein domains, which can be considered as the common currency of 
protein structure and function (43).  Pfam is a large collection of protein domains and 
families. Its scientific goal is to provide a complete and accurate classification of protein 
families and domains. The Pfam database is accessible via the Web and available in several 
different downloadable formats (http://pfam.sanger.ac.uk ). Currently Pfam matches 72% of 
known protein sequences, but for proteins with known structure Pfam matches 95%, which 
represents the likely upper bound.  
Function prediction is filled with potential pitfalls such as considerable sequence divergence, 
non-equivalent functions of homologues and non-identical multi-domain architectures. 
Detecting non-enzymatic regulatory domains is essential to predict a protein’s cellular role, 
binding partners and subcellular localisation. Such domains are usually divergent in sequence 
and occur in contrasting multi-domain contexts. This leads to difficulties unravelling the 
evolution and function of multi-domain proteins. These problems are addressed by the 
SMART Web tool as a database for signalling domains. SMART (a Simple Modular 
Architecture Research Tool) allows the identification and annotation of genetically mobile 
domains and the analysis of domain architectures (http://SMART.embl-heidelberg.de). More 
than 400 domain families found in signaling, extra-cellular and chromatin-associated proteins 
are detectable. These domains are extensively annotated with respect to phyletic distributions, 
functional class, tertiary structures and functionally important residues (44).  
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Both of these two bioinformatics tools, SMART and Pfam, are used extensively for the 
present study in order to analyze the protein architecture of known protective antigens. 
1.6. Model Pathogens for the MetaVaccinology Approach 
1.6.1 Streptococcus agalactiae 
Invasive bacterial infections and the ensuing severe inflammatory response remains a 
significant cause of morbidity and mortality in human newborns and adults. Group B 
Streptococci (GBS), or Streptococcus agalactiae, is the most common cause of life-
threatening bacterial infection in human newborns. These bacteria are Gram-positive, β-
hemolytic, chainforming cocci that are normal residents of the vaginal flora in 25% of healthy 
women. Transmission of GBS from colonized mothers to the newborn can occur in utero 
owing to ascending infection or during birth when the neonate aspirates contaminated 
amniotic/vaginal fluids. Affected newborns include preterm, low birth weight and full-term 
infants GBS disease in newborns is classified as early-onset disease (EOD) or late-onset 
disease(LOD), depending on the age of the infant at the time of disease manifestation. 
Maternal colonization is a prerequisite for EOD, and infection presents in infants within a few 
hours to days of life (≤7 days of age). EOD manifests as respiratory failure and pneumonia 
that rapidly progresses into bacteremia and septic shock syndrome. In contrast, LOD is 
characterized by bloodstream infection, with a high risk of progression to meningitis. LOD 
can present in infants up to several months in age (7–90 days) (45). 
Studies demonstrate that pregnant women, who have opsonically active levels of antibodies to 
GBS, are unlikely to deliver babies that suffer from GBS infections. For example, in one 
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study, 88% of babies were protected against GBS Ia if the maternal anti-GBS Ia antibody was 
greater than 5 µg/ml. Unfortunately, the majority of women do not have adequate levels of 
such antibody (66% UK and 88% USA). This knowledge is the basis of the vaccination idea 
(46). Human isolates of GBS express a capsular polysaccharide (CPS), a major virulence 
factor that helps the microorganism evade host defence mechanisms. Isolates of GBS can be 
divided into nine CPS serotypes (Ia Ib, II, III, IV, V, VI, VII and VIII) each antigenically and 
structurally unique. In the 1930s, Rebecca Lancefield established that protection against GBS 
infection in mice could be achieved using CPS-specific polyclonal rabbit serum. CPS-tetanus 
toxoid conjugate vaccines effective against all nine currently identified GBS serotypes have 
been prepared and were shown to induce functionally active CPS-specific IgG. Clinical trials 
of conjugate vaccines prepared with purified CPS types Ia, Ib, II, III and V have demonstrated 
that these preparations are safe and immunogenic. Not unexpectedly, these preparations do 
not offer protection against other GBS serotypes, such as type VIII, prevalent in other regions 
of the world. As an alternative to CPS-based vaccines, a number of groups have explored the 
development of vaccines based on antigenic proteins. So far, however, the protein antigens 
investigated have been restricted to particular serotypes and no complete cross-serotype 
protection has been achieved (47). To address this need, efforts are ongoing to develop a 
universally effective vaccine for GBS disease that exploits the recently acquired genomic 
sequences of GBS strains, and to then use this information to identify new candidate antigens 
of global relevance. As deeply mentioned above, GBS is the one of the first organism that 
Reverse Vaccinology approach is used, by using pan-genome information.  
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Figure 10: Current status of GBS vaccine research and development, CPS, capsular 
polysaccharide; LmbP, laminin binding protein; Sip, surface immunogenic protein 
(47).  
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1.6.2  Staphylococcus aureus 
Staphylococcus aureus is an important gram positive bacterial pathogen that causes skin and 
soft-tissue infections as well as life-threatening bacteraemias with metastatic complications, 
such as pneumonia, endocarditis, septic arthritis and osteomyelitis (48). Methicillin-resistant 
S. aureus (MRSA) isolates are resistant to all available penicillins and other β-lactam 
antimicrobial drugs. They were once confined largely to hospitals, other health care 
environments, and patients frequenting these facilities. Since the mid-1990s, however, there 
has been an explosion in the number of MRSA infections reported for populations lacking risk 
factors for exposure to the health care system. This increase has been associated with the 
recognition of new MRSA strains, often called community-associated MRSA (CA-MRSA) 
strains that have been responsible for a large proportion of the increased disease burden 
observed in the last decade. These CA-MRSA strains appear to have rapidly disseminated 
among the general population in most areas of the United States and affect patients with and 
without exposure to the health care environment (49). 
The pathogenicity of S. aureus is particularly complex, involving numerous bacterial products 
as well as elaborated regulation pathways. S. aureus is able to produce a wide range of toxins 
showing a deleterious effect on cell integrity and functions. Most of these factors (e.g., toxic 
shock syndrome toxin-1, exfoliatin toxins A and B, Panton-Valentine leukocidin, 
enterotoxins, and hemolysins) contribute to the virulence of clinical isolates in the context of 
acute infections (50). In addition to these excreted compounds, S. aureus is able to produce 
several cell wall–associated proteins allowing interactions with host plasma or extracellular 
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proteins, such as fibronectin, fibrinogen, collagen, vitronectin, laminin, and bone sialoprotein.  
No immunological therapy and/or prophylaxis for S. aureus infections is available, but it 
might be possible as (i) previous infective exposure to the pathogen results in subsequent less 
severe infections; (ii) patients with higher anti-staphylococcal antibody levels are less likely 
to contract staphylococcal infections and (iii) a combined killed-whole bacteria plus toxoid 
vaccine showed 50–70% protection against bovine mastitis. Historically, a variety of whole 
bacteria and toxoid anti-staphylococcal preparations were used in clinical and veterinary 
trials, with little benefit and common adverse reactions. An ideal vaccine against S. aureus 
would aim to prevent bacterial adherence, promote phagocytic killing and/or neutralize toxic 
exoproteins, and be optimally directed to one or more well-characterized antigenic targets 
expressed during infection (51). We used S. aureus as a second model organism for 
MetaVaccinology approach in order to identify new vaccine candidate against this life-
threatening pathogen. 
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1.7 Aim of the study 
The Reverse Vaccinology approach, defined at the beginning of this century, opened the way 
to Genomics applied to vaccine research, by shifting the paradigm of vaccine discovery from 
conventional culture-based methods to high-throughput genome-based approaches for the 
development of recombinant protein-based vaccines. These are comprehensive, large-scale 
approaches, where vaccine candidates are selected according to their in silico predicted 
subcellular localization and then screened in relevant animal models. These genome-based 
approaches have been successfully applied to a range of bacteria, including Neisseria 
meningitidis serogroup B (21), Streptococcus agalactiae (25), Chlamydia trachomatis (52), 
Chalmydia pneumoniae (53), Bacillus anthracis (54), Bacillus anthracis  55), Brucella 
melitensis (56) and, very recently to extraintestinal pathogenic Escherichia coli (26) 
addressing challenging human pathogens for which conventional methods failed to identify a 
vaccine.  
Besides reaching their main goal of identifying good vaccine candidates, these efforts 
produced also a huge amount of molecular knowledge related to the basic biology and the 
pathogenesis mechanisms of many bacteria, examples being breakthrough discoveries of pili 
in pathogenic Streptococci (57) and of innate immunity subverting systems in staphylococci 
and meningococci (58). Nevertheless, the question of which are the elemental molecular 
properties that can be used to in silico predict the few bacterial proteins able of eliciting a 
protective immune response, and thus to be used as effective vaccine components, among the 
complete bacterial proteome remains a challenge. Moreover, these approaches still require 
labor intensive activities in the wet lab to find out, among the large number of secreted and 
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surface exposed proteins, those very few which are protective. For these reasons, in silico 
methods for the selection of possible new vaccine candidates are still an attractive topic in 
vaccine discovery processes.  
The aim of the present study is to analyze the structural and molecular properties of these 
known bacterial protective antigens in order to (i) investigate possible common molecular 
features among these bacterial protective antigens and (ii) extract possible predictive rules 
leading to a simplification in the vaccine discovery process based on the in silico prediction of 
possible new protective antigens.  Group B Streptococcus and S. aureus are used as model 
pathogens to develop this new vaccine discovery tool.  
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2. MATERIAL AND METHODS 
2.1 Meta-analysis of bacterial protective antigens  
A comprehensive list of bacterial antigens described as potential vaccine candidates was 
created from literature data and from on line available databases, e.g. the VIOLIN web site 
(http://www.violinet.org , 59). 115 different protective antigens from 23 bacteria, both gram 
negative and gram positive, and the corresponding proteins sequences were considered for 
this process. A systematic analysis is carried out for this dataset using different bioinformatics 
tools, looking for conserved molecular features at the following molecular levels: primary 
sequence (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins), domain 
occurrence (Pfam, http://pfam.sanger.ac.uk/) protein architecture (SMART, http://smart.embl-
heidelberg.de/smart/set_mode.cgi?GENOMIC=1) and 3D structure (PDB and Pfam Clans). 
The analysis of the alignments within the protective antigens was carried out by using 
ClustalW (http://www.ebi.ac.uk/clustalw/). 
 
2.2 Bacterial Surface Digestion of Streptococcus agalactiae 
8 different Streptococcus agalactiae strains, belonging to the most important disease-causing 
serotypes Ia (515 and A909), Ib (H36B), II (18RS21), III (COH1 and NEM316), and V (2603 
and CJB111) were plated o/n in blood agar  separately (Trypticase™ Soy Agar II with 5% 
sheep blood, Becton Dickinson & Co., Heidelberg, Germany). The bacteria colonies were 
grown at 37°C in 200 ml of Todd-Hewitt broth (THB) in the presence of 5% CO2 until an 
OD600 of 0.3 was reached.  Bacteria were harvested by centrifugation at 3,500 x g for 10 
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min at 4°C, and washed twice with PBS. Cells were resuspended in 800 µL of PBS containing 
40% sucrose (pH 7.4 for trypsin or papain digestions and pH 6.0 for proteinase K digestion). 
Digestions were carried out with 10 µg trypsin (Promega, Madison, U.S.A) or 5 µg proteinase 
K (Sigma, St. Louis, USA) for 30 min at 37°C..  Bacterial cells were then spun down at 3,500 
x g for 10 min at 4°C and the supernatants were filtered through 0.22 µm pore-size filters 
(Millex, Millipore, Beford, U.S.A). Protease reactions were stopped with formic acid at 0.1% 
final concentration. Before analysis, PBS and sucrose were removed by off-line desalting 
procedure using OASIS cartridges (Waters, Milford, USA) following producer’s protocol. 
Desalted peptides were concentrated with a Centrivap Concentrator (Labconco, Kansas City, 
U.S.A), and kept at -20°C until further analysis. 
2.2. 1 Bacterial Surface Double Digestion 
Streptococcus agalactiae strains were cultured and surface-digested as described above. 
Digestion supernatants were then denatured and reduced with Rapigest® (Waters) and 5 mM 
DTT at 100°C respectively for 10 min and an additional o/n proteolytic step with 2 µg trypsin 
(Promega) at 37°C was performed. The second digestion reaction was stopped with formic 
acid at 0.1% final concentration. The peptide mixtures were then desalted and concentrated as 
described above and stored at -20°C until further analysis.  
2.2.2 Protein Identification By Nano-LC/MS/MS 
Peptides were separated by nano-LC on a NanoAcquity UPLC system (Waters) connected to 
a Q-ToF Premier Electro Spray Ionization (ESI) mass spectrometer equipped with a 
nanospray source (Waters). Samples were loaded onto a NanoAcquity 1.7µm BEH130 C18 
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column (75µm X 25mm, Waters), through a NanoAcquity 5µm Symmetry® C18 trap column 
(180µm X 20mm, Waters). Peptides were eluted with a 120-min gradient of 2–40% of 98% 
acetonitrile, 0.1% formic acid solution at a flow rate of 250 nL/min. The eluted peptides were 
subjected to an automated data-dependent acquisition, using the MassLynx software, version 
4.1 (Waters), where a MS survey scan was used to automatically select multicharged peptides 
over the m/z ratio range of 300–2,000 for further MS/MS fragmentation. Up to eight different 
components were subjected to MS/MS fragmentation at the same time. For all samples, a 
second nano-LC-MS/MS analysis was carried out for the selective fragmentation of mono-
charged peptide species. 
After data acquisition, individual MS/MS spectra were combined, smoothed and centroided 
using ProteinLynx, version 3.5 (Waters) to obtain the peak list file. The Mascot Daemon 
application (Matrixscience Ltd., London, UK) was used for the automatic submission of data 
files to an in-house licensed version of MASCOT, version 2.2.1, running on a local server. 
Protein identification was achieved by searching in a locally created database containing 
protein sequence data derived from the eight completely sequenced GBS strains.The 
MASCOT search parameters were set to (i) 1 as number of allowed missed cleavages (only 
for trypsin digestion), (ii) 0.3Da as peptide tolerance, and (iii) 0.3Da as MS/MS tolerance. 
Only significant hits were considered, as defined by the MASCOT scoring and probability 
system. The score thresholds for acceptance of peptide identification were ≥18 for trypsin 
digestion or ≥36 for proteinase K and papain digestions.  
 
  
38
2.3 Selection of MetaV candidates 
2.3.1 MetaV Antigens for GBS 
UniProt was used for obtaining the sequence information of the GBS genomes 
(http://www.uniprot.org/ ).  The corresponding protein sequence information from the UniProt 
knowledgebase was scanned for the occurrence of the MetaV molecular features and 
occurance of the multiple internal repeats (60). Prospero was used to scan the GBS genomes 
for ORFs with more than two internal repeats combined to PSORTb to predict their possible 
subcellular localization, and ten multiple internal repeat-containing proteins were added to the 
list. GBS specific ORFs were obtained from the genomic analysis carried out by Tettelin et al. 
(61).  
2.3.2 Selection of MetaV candidate antigens for S. aureus 
The MetaV list for S. aureus is prepared as described above for GBS. Briefly, UniProt was 
used for obtaining the sequence information of the NCTC 8325 strain of Staphylococcus 
aureus (http://www.uniprot.org/).  The corresponding protein sequence information from the 
UniProt knowledgebase was scanned for the occurrence of the MetaV molecular features and 
occurance of the multiple internal repeats. Prospero was used to scan the NCTC 8325  
genome for ORFs with more than two internal repeats combined to PSORTb to predict their 
possible subcellular localization, and ten multiple internal repeat-containing proteins were 
added to the list.  
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2.5 Cloning, Expression and Purification of Selected GBS Proteins 
2603 V/R strain was used as source of DNA for amplification of selected MetaVaccinology 
candidates. Genes coding for the protein SAG_0954 was cloned as C-terminal His-tag fusion 
protein and then expressed and purified as already reported (25).  PCR primers were designed 
to amplify gene without predicted signal peptide coding sequences for all proteins. PCR 
fragments were cloned by using the Polymerase Incomplete Primer Extension (PIPE) method, 
developed by GNF (Genomics Institute of the Novartis Research Foundation, San Diego, CA, 
USA). All cloning operations were achieved by transforming HK100 competent cells with 
PCR products (I-PCR) immediately following amplification mixed with the V-PCR of 
SpeedET vector (N-term 6xHis tag) (62) . Protein expression was achieved maintainig the 
cultures at 25°C for 4h after the induction using arabinose 0.2 % final concentration. 
Procedures for protein purification were as described in, briefly cells were harvested by 
centrifugation and lysed in “B-PER buffer” (Pierce) containing lysozyme 1mg\ml, DNAse 0.5 
mg\ml and COMPLETE inhibitors cocktail, (Roche). The cell-lysate was clarified by 
centrifugation and applied onto His-Trap HP column (Armesham Biosciences) pre-
equilibrated in buffer containing 10mM imidazole. Protein elution was performed using an 
imidazole gradient (25). Protein concentration was estimated using BCA assay (Pierce).  
SAG_0954, SAG_0416, SAG_0771 were kindly provided by GBS project of Novartis 
Vaccines.  
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Table 2: PCR primers designed to amplify corresponding gene 
Gene ID    
Sequence of Primers 
SAG_1386 5’-CTGTACTTCCAGGGCTTTATAGTATTTTATACTTCAAATAGA-3’ (forward) 
  5’-AATTAAGTCGCGTTAATTTACAACCACAGGATCGCCTGGATT-3’ (reverse) 
SAG_1333 5’-CTGTACTTCCAGGGCGACCAAGTCGGTGTCCAAGTTATAGG-3’ (forward), 
5’-AATTAAGTCGCGTTAAGTACCAATTTTAGCTTCTGTTACTTG-3’ (reverse). 
SAG_0907 5’-CTGTACTTCCAGGGCCAAGAACACAAAAATTCTCATCATATT-3’ (forward), 
5’-AATTAAGTCGCGTTAATGGTGATGATGACCTACATGTGC-3’ (reverse). 
SAG_2148 5’- CTGTACTTCCAGGGCTTACCACTTTCAGTAAGCGCAGCA-3’ (forward), 
5’- AATTAAGTCGCGTTATTAATACCAGCCGTTACTATTCCAAA-3’ (reverse). 
SAG_1350 5’- CTGTACTTCCAGGGCACAAGTCCTGTTTTTGCGGATC-3’ (forward), 
5’- AATTAAGTCGCGTTATAAACCATTTTCAATAGGTTCTTGAG-3’ (reverse). 
SAG_0017 5’-CTGTACTTCCAGGGCAACGCTGATGACTTTGACTCGAAAATTG-3’(forward), 
5’- AATTAAGTCGCGTTAAGTAGCTGTAGCTGTAGTTGTAGC-3’ (reverse). 
 
2.4 Cloning, Expression and Purification of Selected Staphylococcus aureus Proteins 
NCTC 8325 strain was used as source of DNA for amplification of selected MetaVaccinology 
candidates. All the proteins are cloned, expressed and purified according to procedures 
described above for the GBS proteins. 
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2.5 Active Maternal Immunization for GBS proteins 
A maternal immunization/neonatal pup challenge model of GBS infection was used to verify 
the protective efficacy of the MetaV candidates as previously described in (16). In brief, CD-1 
female mice (6-8 weeks old) were immunized before breeding, on days 1, 21 and 35. The 
mice received either PBS or 20 µg of protein per dose. Mice were bred 2-7 days after the last 
immunization. Within 48 h of birth, pups were injected intraperitoneally with 50 µl of GBS 
COH1 culture corresponding to a LD90. Challenge inocula were prepared starting from frozen 
cultures diluted to the appropriate concentration with THB. Survival of pups was monitored 
for 2 days after challenge. Protection was calculated as (percentage deadControl minus 
percentage deadVaccine) divided by percentage deadControl multiplied by 100. The 515 
(GBS-01) and COH1 (GBS-02) hypervirulent strains were used for challenging the mice. 
2.6 S. aureus Immunization Experiments 
CD-1 female mice (5 week old) were intraperitonally immunized with 20 µg protein+ALUM, 
on days 1 and 14, Then on 24th day, mice are intraperitonally challenged with 100 µl of 
S.aureus Newman culture corresponding to 5x108 CFU/mice.  Survival of mice was 
monitored for fifteen days. SAOUHSC_00427, SAOUHSC_01949, SAOUHSC_02979, 
SAOUHSC_02576 and a protective S. aureus antigen (as a positive control) were used for the 
immunization schema against S. aureus (SA-1).  The same immunization schema was used to 
test proteins SAOUHSC_00356, SAOUHSC_00400, SAOUHSC_00248, SAOUHSC_00256, 
SAOUHSC_00994, SAOUHSC_00392  (SA-2) 
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2.7. Functional Characterization of SAG_1333 
2.7.1 xCELLigence System with carcinomic human alveolar basal epithelial cells (A549)
  
The xCELLigence measurement was performed with the xCELLigence System from Roche 
that monitors cellular events in real time without the incorporation of labels 
(http://www.roche-applied-science.com/sis/xcelligence/ezhome.html). The System measures 
electrical impedance across interdigitated micro-electrodes integrated in the bottom of tissue 
culture E-Plates. The impedance measurement provides quantitative information about the 
biological status of the cells, including cell number, viability, and morphology.  
Prior to seeding the cells in the E-Plates, the concentration of the cell-suspension was 
determined by Invitrogen™ Countess® Automated Cell Counter.  5*104 A549 cells were 
seeded in 14 of 16 wells. The E-Plates were filled with 50µl Medium (Invitrogen™ RPMI 
1640 Medium 1X, liquid, 2 % FBS (Fetal Bovine Serum), 1% Antibiotics) and 50µl cell 
suspension. The E-Plates were incubated at room temperature for 30 min and then at 37°C for 
24h for cells to reach confluence in the wells. After 24h incubation, the supernatant was 
removed in the E-plates and 50µl of the reactant is added. (The level of concentrations is 
listed on Table 3 below). The behavior of the cells was monitored by the xCELLigence 
System for the next 24h at 37°C. 
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Table 3: Concentrations of compounds 50µl of reactants were added when the cells have 
reached confluence. The reactants were diluted in PBS. α :a hemolysin from GAS β: 
137mM NaCl 2.7mM KCl 4.3mM NaHPO4 1.47mM KH2PO4 γ: A non-toxic protein of 
S.aureus as control 
Compounds Concentrations  
Positive 
control 
Pore forming toxin α     
20µl/ml 
   
 
  
Negative 
Control 
PBSβ 1:1000 1:100 1:10     
Negative 
Control 
Non toxic proteinγ 25µl/ml       
 N-term of 
SAG_1333 
25µl/ml 10µl/ml      
 Full length 
SAG_1333 
 
25µl/ml 
 
10µl/ml 
 5 
µl/ml 
    
In the wells with non toxic protein, SAG_1333 and the N-term of SAG_1333, different 
concentrations of AMP were added:  
 AMP 0mM 0.5mM 5mM     
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2.7.2. xCELLigence with mouse leukemic monocyte macrophage cell (Raw cells) 
The same procedure used for A549 cell line was applied to Raw cells. Table 4 shows the 
compounds and concentrations used for the experiments. All experiments were repeated at 
least two times for both cell lines.  
 
Table 4: Concentrations of compounds 50µl of reactants were added when the cells have 
reached confluence. The reactants were diluted in PBS. α: α heamolysin from GAS β: 
137mM NaCl 2.7mM KCl 4.3mM NaHPO4 1.47mM KH2PO4 γ: A non-toxic protein of 
S.aureus as control 
Compounds Concentrations  
Positive 
control 
Pore forming toxin α 20µl/ml    
 
  
Negative 
Control 
PBSβ 1:1000 1:100 1:10     
Negative 
Control 
Non toxic proteinγ 25 µl/ml       
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 N-term of 
SAG_1333 
25µl/ml 10µl/ml      
 Full length 
SAG_1333 
100µl/ml  50µl/ml  25µl/ml  10µl/ml 5 
µl/ml 
  
AMP with different concentrations were added:  
 AMP 0mM 0.1mM 1mM 2.5mM 5mM   
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3. RESULTS AND DISCUSSION 
3.1 Main Question: What makes an antigen protective?  
Today, we have many genomic tools to investigate the microbial world as summarized in the 
introduction. Moreover, all these different instruments open new insights for vaccinology 
science but the main question remains constant: what makes an antigen protective and why? 
Could we select this set of protective antigens by just using in-silico approaches? Reverse 
Vaccinology made a step forward to reply this question and caused a paradigm shift by 
selecting all surface associated and secreted proteins as potential vaccine candidates. But even 
this progressive approach selects hundreds of proteins to be tested in in-vivo models and the 
percentage of protective antigens within all set is very low.  
In the present study, we tried to answer this simple but basic question: are there any 
recurring/common molecular features within all identified protective antigens? If there are, 
could we use these recurring signatures as predictive features to identify new vaccine 
candidates?  According to our knowledge, this is the first time that this question is answered, 
and yes…  
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3.2 Systematic Analysis of Known Protective Antigens 
In order to answer this fundamental question; a comprehensive list of bacterial antigens 
described as potential vaccine candidates, based on in vivo animal models and/or on in vitro 
assays, was created from literature data and from available on line databases, e.g. the VIOLIN 
web site (59).  We were able to collect information from 115 different protective antigens 
from 23 bacterial pathogens, of those 13 are gram negative and 10 are gram positive.  In 
particular, Helicobacter pylori, Escherichia coli, Haemophilus influenzae Neisseria 
meningitidis serogroup B, Pasteurella haemolytica, Pseudomonas aeruginosa , Yersinia 
pestis,  Campylobacter jejuni, Brucella abortus, Brucella burgdorferi, Brucella melitensis, 
Bordetella  pertussis, Pseudomonas aeruginosa, Streptococcus pneumoniae, Streptococcus 
pyogenes, Streptococcus agalactiae, Staphylococcus aureus Mycobacterium tuberculosis, 
Bacillus anthracis, Listeria monocytogenes, Clostridium difficile, Clostridium tetani and 
lastly Clostridium botulinum were used to construct our data set. 
The corresponding proteins sequences of all these 115 different antigens became our total 
protective antigens dataset. We carried out a systematic analysis of this dataset using different 
bioinformatic tools, looking for conserved molecular features at the following molecular 
levels of each protein: primary sequence (BLAST), domain occurrence (PFam), protein 
architecture (SMART) and 3D structure (PDB and Pfam Clans). 
The results of this meta-analysis revealed that protective antigens have recurring functional 
and/or structural units, which were in most cases associated to either specific domain from the 
Pfam databases or to a conserved protein architecture organized in a variable number of 
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multiple internal repeats. The rest of the protective antigens not showing these properties were 
found to be either species-specific or genus-specific ORFs by genomic analysis (Figure 11). 
 
Figure 11: Classification of known bacterial protective antigens. 83 % of the proteins have 
conserved Pfam domains or organized multiple repeats while 13 % are encoded by 
species/genus specific genes with either no domains or species-specific domains. 
 
Then we classified the Pfam domains based on their frequency of occurrence in the dataset of 
bacterial protective antigens and this analysis revealed that 35 Pfam domains are found in 
more than one protective antigen either from the same species or from different species and 
groups (Table 6). 
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Table 6. The recurring Pfam Domains within different protective antigens.  
No Recurring Pfam domains 
Number of 
Species Observed in 
1  PF00691. OmpA.  6 Gram - 
2 PF00082. Peptidase_S8 5 Both Gram - and + 
3 PF01476. LysM.  5 Both Gram - and + 
4 PF05738. Cna_B 4 Gram + 
5 
 PF02872. 5_nucleotid_C.,  
PF00149. Metallophos 3 Both Gram - and + 
6 PF10425. SdrG_C_C 2 Gram + 
7 PF04270. Strep_his_triad   3 Gram + 
8 PF00669, Flagellin_N, PF00670, Flagellin_C  3 Gram + 
9 PF01289, Thiol_cytolysin  3 Gram + 
10 PF03895. YadA. 1 hit.   3 Gram - 
11 PF08428. Rib 2 Gram + 
12 PF05257. CHAP domain 2 Gram + 
13 PF00877. NLPC_P60.   2 Both Gram - and + 
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14 PF02608. Bmp 2 Gram + 
15  PF01547. SBP_bac_1.   2 Both Gram - and + 
16 PF00756. Esterase.  2 Both Gram - and + 
17 PF06013 WXG100  2 Gram + 
18 PF00353. HemolysinCabind. 2 Gram - 
19 PF01742. Peptidase_M27 2 Gram + 
20 PF01473. CW_binding_1.  2 Gram + 
21 PF03212. Pertactin 2 Gram - 
22 PF02395. Peptidase_S6. 2 Gram - 
23 PF04792. LcrV. 1 hit. 2 Gram - 
24  PF01497. Peripla_BP_2. 2 Gram + 
25 PF00593. TonB_dep_Rec.,  PF07715. Plug.   2 Gram - 
26  PF01298. Lipoprotein_5.  2 Gram - 
27 PF02876: Stap_Strp_tox_C 2 Gram + 
28 PF06013: WXG100 2 Gram + 
29 PF00089. Trypsin. 1 hit. 2 Both Gram - and + 
30  PF00118. Cpn60_TCP1. 1 hit.   2 Gram - 
32  PF00497. SBP_bac_3.   1 Gram - 
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33 PF11713. Peptidase_C80. 1 Gram + 
34 PF05031. NEAT  1 Gram + 
35 
PF04488. Gly_transf_sug. 1 hit. 
PF11713. Peptidase_C80. 1 hit.  1 Gram + 
 
On the other hand, primary sequence (BLAST) analysis revealed that only in very few cases 
protective antigens from different species show a significant sequence similarity (>50% ID). 
Table 6 reports representative examples of known bacterial protective antigens, their 
functional classification and the associated molecular features identified by the meta-analysis 
carried out in the present study.  
  
 
  
52
T
ab
le
 7
 –
 F
un
ct
io
na
l c
la
ss
if
ic
at
io
n 
of
 k
no
w
n 
pr
ot
ec
ti
ve
 a
nt
ig
en
s 
an
d 
th
ei
r 
as
so
ci
at
ed
 m
ol
ec
ul
ar
 f
ea
tu
re
s,
 in
cl
ud
in
g 
P
fa
m
 d
om
ai
n/
cl
an
s 
an
d 
oc
cu
rr
en
ce
 o
f 
m
ul
ti
pl
e 
in
te
rn
al
 r
ep
ea
ts
. 
E
xa
m
pl
es
 a
re
 p
ro
vi
de
d 
fo
r 
ea
ch
 f
un
ct
io
na
l 
cl
as
s,
 w
ith
 t
he
 c
or
re
sp
on
di
ng
 %
 o
f 
id
en
tit
y 
ob
ta
in
ed
 b
y 
pr
im
ar
y 
se
qu
en
ce
 a
lig
nm
en
t. 
R
el
at
io
n 
be
tw
ee
n 
di
ff
er
en
t p
ro
te
ct
iv
e 
an
tig
en
s 
be
co
m
e 
ob
vi
ou
s 
on
ly
 lo
ok
in
g 
at
 th
ei
r 
do
m
ai
n 
co
m
po
si
tio
n 
an
d 
pr
ot
ei
n 
ar
ch
ite
ct
ur
e 
or
ga
ni
za
tio
n 
C
la
ss
if
ic
at
io
n 
Su
b-
cl
as
si
fi
ca
ti
on
 
E
xa
m
pl
es
 
%
 I
D
 
P
fa
m
 F
am
ili
es
 a
nd
 C
la
ns
 
F
la
ge
lli
ns
 
 
Fl
ag
el
lin
s 
fr
om
 P
.a
er
ug
in
os
a6
3 , 
E
. 
co
li 
64
, 
C
. 
je
ju
ni
 
65
, H
. p
yl
or
i 6
6  
9-
 4
1 
%
 
PF
00
66
9,
 F
la
ge
lli
n_
N
 
PF
00
70
0,
 F
la
ge
lli
n_
C
 
M
aj
or
 
ou
te
r 
m
em
br
an
e 
pr
ot
ei
ns
 
 
C
33
89
 f
ro
m
 E
. 
co
li 
67
 
, 
P6
 f
ro
m
 H
. 
in
fl
ue
nz
ae
68
 
O
m
p1
6 
fr
om
 B
. a
bo
rt
us
 6
9  
 o
ut
er
 m
em
br
an
e 
po
ri
n 
F 
fr
om
 P
. a
er
ug
in
os
a 
70
 
16
-3
2 
%
 
PF
00
69
1.
 O
m
pA
 
  
53
T
ox
in
s 
      
Po
re
-f
or
m
in
g 
to
xi
ns
 
  
Pl
y 
fr
om
 S
. 
pn
eu
m
on
ia
e 
71
, 
st
re
pt
ol
ys
in
 O
 f
ro
m
 S
. 
py
og
en
es
72
, L
is
te
ri
ol
ys
in
 O
 f
ro
m
 L
. m
on
oc
yt
og
en
es
 
73
 
38
-4
3 
%
 
PF
01
28
9,
 T
hi
ol
_c
yt
ol
ys
in
  
 
A
lp
ha
-t
ox
in
74
 a
nd
 P
an
to
n-
V
al
en
tin
e 
L
eu
co
ci
di
n 
F 
75
  
fr
om
 S
. a
ur
eu
s 
 
 2
4 
%
 
PF
07
96
8.
 L
eu
ko
ci
di
n 
H
em
ol
ys
in
 fr
om
 E
. c
ol
i 2
6  
 
PF
00
35
3.
 
H
em
ol
ys
in
C
ab
in
d.
 
R
ib
os
yl
 tr
an
sf
er
as
es
 
D
if
te
ri
ae
 t
ox
in
 f
ro
m
 C
. 
di
ph
th
er
ia
e 
76
, 
 P
er
tu
ss
is
 
to
xi
n 
fr
om
  
B
. p
er
tu
ss
is
 7
7 , 
 C
ho
le
ra
 t
ox
in
 f
ro
m
  
V
. 
ch
ol
er
ae
 78
 
7-
11
%
 
C
L0
08
4.
 A
D
P-
ri
bo
sy
l  
 
  
54
N
eu
ro
to
xi
ns
 
T
et
an
us
 t
ox
in
 f
ro
m
 C
. 
te
ta
ni
79
 ,
  
B
ot
ul
in
um
 t
ox
in
 
fr
om
 C
. b
ot
ul
in
um
 8
0  
33
 %
 
PF
01
74
2.
 P
ep
tid
as
e_
M
27
 
Se
co
nd
 
m
es
se
ng
er
  
pa
th
w
ay
 a
ct
iv
at
or
s 
to
xi
n 
A
 a
nd
 to
xi
n 
B
  f
ro
m
 C
. d
iff
ic
ile
 81
 
47
 %
 
PF
01
47
3.
 C
W
_b
in
di
ng
_1
.  
PF
04
48
8.
 G
ly
_t
ra
ns
f_
su
g 
PF
11
71
3.
 P
ep
tid
as
e_
C
80
. 
E
xt
ra
ce
llu
la
r 
en
zy
m
es
 
Pr
ot
ea
se
s 
C
5a
 p
ep
tid
as
es
 f
ro
m
 S
. a
ga
la
ct
ia
e 
82
, S
py
04
16
 f
ro
m
 
S.
 
py
og
en
es
38
 
,p
rt
A
 
fr
om
 
S.
 
pn
eu
m
on
ia
83
 
, 
N
M
B
19
69
 fr
om
 N
. m
en
in
gi
tid
is
84
 
9-
29
 %
 
PF
00
08
2.
 P
ep
tid
as
e_
S8
 
Sp
eB
 fr
om
 S
. p
yo
ge
ne
s 
85
 
 
PF
01
64
0.
 P
ep
tid
as
e_
C
10
  
  
55
Pe
ni
ci
lli
n-
bi
nd
in
g 
pr
ot
ei
n 
(D
-a
la
ny
l-
D
-a
la
ni
ne
 
ca
rb
ox
yp
ep
tid
as
e)
 fr
om
 S
.p
yo
ge
ne
s 
86
 
 
PF
07
94
3.
 P
B
P5
_C
 
PF
00
76
8.
 P
ep
tid
as
e_
S1
1 
5’
nu
cl
eo
tid
as
es
 
N
uc
A
 
fr
om
 
H
. 
in
flu
en
za
 
87
, 
Sp
y0
87
2 
fr
om
 
S.
 
py
og
en
es
 88
, S
A
G
_1
33
3 
fr
om
 S
. a
ga
la
ct
ia
e 
th
is
 s
tu
dy
 
19
-6
4 
%
 
PF
02
87
2.
 5
_n
uc
le
ot
id
_C
 
PF
00
14
9.
 M
et
al
lo
ph
os
.  
Ir
on
 u
pt
ak
e 
an
d 
tr
an
sp
or
t 
sy
st
em
s 
H
em
e 
bi
nd
in
g 
pr
ot
ei
ns
  
Is
dA
 a
nd
 Is
dB
 fr
om
 S
. a
ur
eu
s 
89
, 9
0  
18
 %
 
PF
05
03
1.
 N
E
A
T
  
T
on
B
 
de
pe
nd
en
t 
re
ce
pt
or
s 
Ir
oN
91
 ,
Fy
uA
 9
1 , 
C
hu
A
 9
2 , 
Ih
a 
92
, 
Ir
eA
 9
2 a
nd
 I
ut
A
 
92
fr
om
 E
.c
ol
i ,
 T
bp
A
 a
nd
 T
bp
B
 f
ro
m
 P
. h
ae
m
ol
yt
ic
a 
93
 
10
- 3
2 
%
 
PF
07
71
5.
 P
lu
g 
PF
00
59
3.
 T
on
B
_d
ep
_R
ec
   
  
56
Ir
on
 tr
an
sp
or
t 
Pi
aA
 fr
om
 S
. p
ne
um
on
ia
e 
94
 
 
PF
01
49
7.
 P
er
ip
la
_B
P_
2 
   
O
th
er
 
so
lu
te
 
bi
nd
in
g 
pr
ot
ei
ns
 
 
P3
9 
fr
om
 B
. m
el
ite
ns
is
 9
5 , 
po
tD
 f
ro
m
 S
. p
ne
um
on
ia
e 
96
, 
C
ja
A
 
fr
om
 
C
. 
je
ju
ni
 
97
, 
G
N
A
19
46
 
fr
om
 
N
. 
m
en
in
gi
tid
is
 21
 
5-
11
%
 
C
L0
17
7.
 P
B
P 
A
dh
es
iv
e 
st
ru
ct
ur
es
 
w
it
h 
bi
nd
in
g 
pr
op
er
ti
es
 
to
 
E
C
M
 
an
d/
or
 
se
ru
m
 p
ro
te
in
s 
C
na
_B
 
do
m
ai
n 
co
nt
ai
ni
ng
 p
ro
te
in
s 
P
ili
 s
ub
un
its
 f
ro
m
 S
. p
yo
ge
ne
s 
98
 , 
 S
. a
ga
la
ct
ia
e 
99
,  
S.
 p
ne
um
on
ia
e 
10
0  ,
C
na
 1
01
, S
dr
D
10
2  a
nd
 S
dr
E
10
2 
fr
om
 
S.
 a
ur
eu
s 
 
6-
 5
8 
%
  
 
PF
05
73
8.
 C
na
_B
 
 
Pr
ot
ei
ns
 
co
nt
ai
ni
ng
 
va
ri
ab
le
 n
um
be
rs
 o
f 
in
te
rn
al
 re
pe
at
s 
 
Fn
bp
A
 
10
1 , 
cl
um
pi
ng
 
fa
ct
or
 
A
10
2  
, 
Sd
rC
 
10
2 a
nd
 
Sd
rD
10
2  
fr
om
 
S.
 
au
re
us
, 
SA
N
_1
48
5 
fr
om
 
S.
 
ag
al
ac
tia
e 
40
 
10
- 5
8 
%
 
PF
10
42
5.
 S
dr
G
_C
_C
 
  
57
 
 
M
 p
ro
te
in
 fr
om
 S
. p
yo
ge
ne
s 
10
3  
 
PF
02
37
0.
 M
. 
L
eu
ci
ne
 ri
ch
 p
ro
te
in
 L
rr
G
 fr
om
 S
. a
ga
la
ct
ia
e 
10
4  
 
L
eu
ci
ne
 ri
ch
 re
pe
at
s 
R
ib
 p
ro
te
in
 1
05
 a
nd
 C
 p
ro
te
in
 a
lp
ha
-a
nt
ig
en
 f
ro
m
 S
. 
ag
al
ac
tia
e 
10
6  
 
PF
08
82
9.
 A
lp
ha
C
_N
.  
PF
08
42
8.
 R
ib
 
Fa
ct
or
 H
 b
in
di
ng
 p
ro
te
in
 fr
om
 N
. m
en
in
gi
tid
is
 10
7 
 
PF
08
79
4.
Li
po
pr
ot
_C
 
O
th
er
s 
H
ep
ar
in
 
bi
nd
in
g 
pr
ot
ei
n 
G
N
A
21
32
 
fr
om
 
 
N
. 
m
en
in
gi
tid
is
10
8 , 
T
bp
B
 fr
om
 H
.  
in
flu
en
za
e 
10
9  
11
 %
 
PF
01
29
8.
 L
ip
op
ro
te
in
_5
 
  
58
N
ad
A
 f
ro
m
  N
. m
en
in
gi
tid
is
 1
10
 , 
U
sp
A
1 
an
d 
U
sp
A
2 
fr
om
 M
. 
ca
th
ar
ra
lis
 1
11
, 
Ya
dA
 a
nd
 Y
ad
C
 f
ro
m
 Y
. 
pe
st
is
 11
2 , 
C
44
24
 fr
om
 E
. c
ol
i 9
2  
8-
 2
3 
%
 
PF
03
89
5.
 Y
ad
A
 
Ph
tA
 1
13
, P
ht
B
 1
13
, S
P_
11
74
 2
9  
fr
om
 S
. p
ne
um
on
ia
e 
, 
SA
G
_0
90
7 
fr
om
 S
. a
ga
la
ct
ia
e 
th
is
 s
tu
dy
 
12
- 6
5 
%
 
PF
04
27
0.
 S
tr
ep
_h
is
_t
ri
ad
   
B
m
pA
 f
ro
m
 B
. B
ur
gd
or
fe
ri
 1
14
 , 
SA
G
_0
95
4 
fr
om
 S
. 
ag
al
ac
tia
et
hi
s 
st
ud
y  
12
 %
  
 
PF
02
60
8.
 B
m
p 
Pe
rt
ac
tin
 
fr
om
 
B
. 
pe
rt
us
si
s 
11
5 , 
H
ap
 
fr
om
 
H
. 
in
flu
en
za
 11
6 , 
N
M
B
19
98
 fr
om
 N
. m
en
in
gi
tid
is
 11
7  
3-
28
 %
 
PF
03
21
2.
 P
er
ta
ct
in
 
PF
02
39
5.
 P
ep
tid
as
e_
S6
. 
  
59
P
ro
te
in
s 
w
it
h 
ge
ne
ri
c 
ce
ll 
w
al
l 
bi
nd
in
g 
do
m
ai
ns
 
 
L
ys
M
 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
s 
P6
0 
fr
om
  L
. m
on
oc
yt
og
en
es
 1
18
  I
nt
im
in
 fr
om
 E
. c
ol
i 
11
9 , 
E
bp
s 
fr
om
 S
. 
au
re
us
 1
20
 ,
 T
sp
A
 f
ro
m
 N
ei
ss
er
ia
 
m
en
in
gt
id
is
 s
er
og
ro
up
 B
 1
58
, 
SA
G
_1
38
6 
fr
om
 S
. 
ag
al
ac
tia
e 
th
is
 s
tu
dy
  
30
 %
 
PF
01
47
6.
 L
ys
M
 
 
C
H
A
P 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
s 
Pc
sB
 fr
om
 S
. p
ne
um
on
ia
e2
9  
 
PF
05
25
7.
 C
H
A
P 
do
m
ai
n 
C
ho
lin
e-
bi
nd
in
g 
m
ot
if
s 
Ps
pA
 fr
om
 S
. p
ne
um
on
ia
e 
12
1  
 
PF
01
47
3.
 C
W
_b
in
di
ng
_1
 
Ps
pC
 fr
om
 S
. p
ne
um
on
ia
e 
12
1  
 
PF
05
06
2.
 R
IC
H
. 
 
  
60
3.3 The MetaVaccinology approach: a new knowledge-driven predictive discovery tool 
based on conserved molecular features in bacterial protective antigens 
Based on the results described above, we formulated the hypothesis that the occurrence of the 
identified molecular features can be predictive of possible protective properties in other 
proteins from other species of interest. In order to test this hypothesis, predictive rules based 
on the occurrence of (i) selected MetaV Pfam domains, (ii) a protein architecture organized in 
multiple internal repeats and (iii) species- or genus-specificity of the corresponding genes 
were defined, and an in silico workflow for the genome wide selection of possible new 
protective antigens in bacterial genomes arranged as reported in Figure 12. The design of such 
approach is intended as a knowledge-driven predictive tool for the selection of possible new 
vaccine candidates in both gram positive and gram negative bacteria.  
Etymologically, Meta- (from Greek: µετά = "after", "beyond", "with", "adjacent", "self"), is a 
prefix used in English (and other Greek-owing languages) to indicate a concept which is an 
abstraction from another concept, used to complete or add to the latter. We named our 
approach as MetaVaccinology, since the knowledge of the predictive rules were abstracted by 
a species-independent meta-analysis of a comprehensive from dataset of protective antigens 
and applied to predict new antigens.   
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Figure 12: The operative steps of MetaVaccinology  
3.4. MetaVaccinology (MetaV) applied to GBS  
In order to provide an initial proof-of-concept of the MetaV selection approach, we applied 
our strategy to GBS. We used the available GBS complete genome of 2603V/R (serotype V), 
the corresponding protein sequence information from the UniProt knowledgebase was 
scanned for the occurrence of the MetaV molecular features. Occurrence of the all MetaV 
core Pfam domains were scanned, and 14 of those that are present in more than one protective 
antigen were used for selection. As a second step, we used Prospero (see M&M) to scan the 
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GBS genome for ORFs with more than two internal repeats. GBS specific ORFs were 
obtained from the genomic analysis carried out by Tettelin et al. (61). A total of 61 MetaV 
candidates were selected by this way (Table 8). 
The list of sixty one selected proteins is shown. Proteins are grouped according to the core 
domains used to select them. For each protein the following information is reported: NCBI 
gene ID, protein annotation and predicted subcellular localization. 
Table 8. The list of GBS MetaVaccinology candidates   
No CHAP Domain Annotation Localization 
1 SAG1998   hypothetical protein membrane 
2   SAG1762  conserved hypothetical protein outside 
3 SAG1683  immunogenic secreted protein, putative outside 
4 SAG1286   conserved hypothetical protein membrane 
5 SAG0598 N-acetylmuramoyl-L-alanine amidase unknown  
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6 SAG0017  PcsB protein  outside 
  LysM Domain     
7 SAG2148 LysM domain protein outside 
8 SAG1386  conserved hypothetical protein membrane 
9 SAG0032 surface immunogenic protein  outside  
  Cna_B     
10 SAG1408  cell wall surface anchor family protein LPXTG  
11 
  
SAG1407   cell wall surface anchor family protein LPXTG  
12 
  
SAG1404  cell wall surface anchor family protein LPXTG  
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13 SAG0651   hypothetical protein unknown  
14 SAG0649   cell wall surface anchor family protein LPXTG  
15 SAG0646  cell wall surface anchor family protein LPXTG  
16 SAG0645   cell wall surface anchor family protein LPXTG  
  Peptidase_S8     
17 SAG2053 serine protease LPXTG  
18 SAG0676  serine protease, subtilase family LPXTG  
19 SAG0416  Protease LPXTG  
20 SAG1236 C5a peptidase LPXTG  
  5_nucleotid_C     
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21 SAG1333 5'-nucleotidase family protein LPXTG  
22 SAG1941  2`,3`-cyclic-nucleotide 2`-phosphodiesterase LPXTG  
  Internal Repeats     
23 SAG1350  Surface antigen-related protein  Outside 
24 SAG0433   surface protein Rib LPXTG  
25 SAK0517 c protein alpha-antigen precursor  Outside 
26 SAG1283 cell wall surface anchor family protein LPXTG 
27 SAG1996 cell wall anchor protein-related protein LPXTG  
28 SAG0421 conserved hypothetical protein LPXTG  
29 SAK0186 iga fc receptor precursor LPXTG  
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30 SAG2063  pathogenicity protein, putative LPXTG  
31 SAG1331 R5 protein LPXTG  
 Strep_his_triad     
 SAG1233  streptococcal histidine triad family protein  Outside 
32 SAG0907  streptococcal histidine triad family protein Lipoprotein 
  FbpA     
33 SAG1190 adherence and virulence protein A unknown  
 Bmp Domain   
34 SAG0954 lipoprotein Lipoprotein 
35 SAG0405 lipoprotein Lipoprotein 
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  WXG100     
36 SAG1039  conserved hypothetical protein Cytoplasm 
37 SAG0230  conserved hypothetical protein Cytoplasm 
  SdrG_C_C     
38 SAG1462  cell wall surface anchor family protein LPXTG  
  NLPC_P60.       
39 SAG0926 Tn916, NLP/P60 family protein   Outside 
  Band_7     
40 SAG0132 SPFH domain/Band 7 family protein   Outside 
  Lipoprotein_9     
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41 SAG0776 YaeC family protein  Lipoprotein 
42 SAG0971 Putative uncharacterized protein  Lipoprotein 
43 SAG1641 YaeC family protein   Outside 
  Gly_transf_sug     
44 SAG1167 Polysaccharide biosynthesis protein CpsM(V) cytoplasm 
 Streptococci-
specific  
    
45 SAG0265 conserved hypothetical protein outside 
46 SAG0371   hypothetical protein outside 
47 SAG0771  cell wall surface anchor family protein LPXTG 
48 SAG0833   hypothetical protein outside 
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49 SAG0973 nisin-resistance protein, putative membrane 
50 SAG1037   hypothetical protein membrane 
51 SAG1127 conserved hypothetical protein outside 
52 
  
SAG1419   hypothetical protein lipoprotein 
53 SAG1491   hypothetical protein outside 
54 SAG1473   hypothetical protein outside 
55 SAG1745   hypothetical protein outside 
56  SAG2056 chromosome assembly-related protein outside 
57  SAG2121   hypothetical protein outside 
58 SAG2021 Surface antigen protein LPXTG 
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59 SAG1197 Hyaluronate lyase  outside 
60 SAG0392 Similar to fibrinogen-binding protein LPXTG 
61 SAG1589 Amino acid permease  membrane 
 
We focused our attention on a representative set of 9 proteins out of 61 MetaV candidates, in 
particular, (i) two extracellular enzymes, i.e. one peptidase S8 and one 5’ nucleotidase, (ii) a 
basic membrane protein, (iii) two proteins with multiple internal repeats, (iv) a histidine triad 
protein, and (v) three proteins with generic cell-wall binding domains, i.e. two LysM and a 
CHAP domain-containing proteins (Table 9).  
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Table 9: The MetaV antigens of GBS selected to be tested in animal model. 
No 2603 V/R Annotation Pfam Domains 
1 SAG_0416 protease, putative  PF00082. Peptidase_S8 
2 SAG_1350 surface antigen-related protein Internal Repeats 
3 SAG_1333 5'-nucleotidase family protein PF02872. 5_nucleotid_C 
4 SAG_0771 cell wall surface anchor family protein Internal Repeats 
5 SAG_0954  Lipoprotein PF02608.Bmp 
6 SAG_0907 streptococcal histidine triad family protein PF04270. Strep_his_triad   
7 SAG_0017 PcsB protein PF05257. CHAP domain 
8 SAG_1386 conserved hypothetical protein PF01476. LysM 
9 SAG_2148 LysM domain protein PF01476. LysM 
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3.5 New Protective Antigens are identified  by MetaVaccinology against GBS  
The corresponding gene sequences from the 2603V/R strain were cloned in E. coli and nine 
proteins were successfully expressed and purified either as full-length or single domains (see 
Materials and Methods). In order to assess their efficacy in term of elicited protective 
immunity against natural infection, we performed in vivo experiments in a maternal 
immunization/neonatal pup challenge mouse model using GBS COH1 and 515 as challenge 
strains. Female mice received three doses (days 1, 21, 35) of either 20 µg antigen or PBS 
combined with Freund’s adjuvant. Mice were then mated, and the resulting offspring 
challenged with a dose of GBS calculated to kill 80 to 90% of the pups. Survival of pups was 
monitored at day 2 after the challenge and protection values were calculated as [(% dead in 
control – % dead in vaccine)/% dead in control] x 100. Among the nine antigens tested in the 
animal model, four were able to induce a significant level of protection as compared to the 
control group, i.e. the 5’ nucleotidase SAG1333 (67%), the histidine-triad protein SAG0907 
(50%), the Bmp protein SAG0954 (41%) and the LysM domain-containing protein SAG1386 
(33%)  (Table 10).  
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Table 10. Protective activity of the selected GBS proteins compared with PBS as 
negative control. Protection was calculated as [(% deadControl - % deadVaccine) / % 
deadControl ] x100.  
(GBS-01)                               
GBS 515 as challenge strain                     
Survival  Survival % Protective 
Efficacy 
Name of the protein n° animals 
SAG_1333 63 of 89 70 67 
SAG_0907 29 of 66 44 38 
SAG_0954 33 of 50 66 41 
SAG_1386 9  of 20 45 28 
PBS 7 of 77 9 * 
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(GBS-02)                               
GBS COH1 as challenge strain                     
Survival  Survival % Protective 
Efficacy 
Name of the protein n° animals 
SAG_0907 23 of 39 59 50 
SAG_1386 33 of 50 66 41 
PBS 7  of 40 18 * 
 
3.5.1 SAG_1333  
Please look at chapter about functional characterization of SAG_1333  
3.5.2 SAG_0907 
SAG_0907 is a histidine triad motif containing protein like PhtA, PhtB, or PhtD that are 
protective cell surface-exposed pneumococcal proteins (113). Humans produce antibodies to 
Pht proteins upon exposure to pneumococcus, and immunization of mice has provided 
protective immunity against sepsis and pneumonia and reduced nasopharyngeal colonization. 
The function of these proteins is not identified yet but there is an on-going discussion on their 
immune evasion and Factor H binding activity (122, 123). S. pyogenes have 2 different 
virulence factors that contain this motif; HtpA and Spy1361. HtpA-immunized mice 
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survived after challenge with GAS strains (isolated from patients) for significantly longer 
periods than sham-immunized mice and Spy 1361 is recently suggested as a vaccine candidate 
and hypothesized that it might play a role in GAS intracellular invasion (124). All these 
proteins are characterized by having an histidine (HxxHxH) motif that usually occurs multiple 
times.  
3.5.3 SAG_0954 
SAG0954 has a Bmp domain as Bmp proteins of Borrelia burgdorferi. BmpA of B. 
burgdorferi plays a significant role in mammalian infection by the Lyme disease spirochete 
and is an important antigen for the serodiagnosis of human infection. It is reported that 
BmpA-directed antibodies significantly inhibited the adherence of live B. burgdorferi to 
laminin (125) and B. burgdorferi lacking bmpA/B were unable to persist in the joints and 
failed to induce severe arthritis (126). Another Bmp domain containing protein P48 of M. 
agalactiae is described as an invariable, constantly expressed, immunodominant, surface 
lipoprotein. A recent report showed that genetic immunization with the immunodominant 
antigen P48 of M. agalactiae stimulates a mixed adaptive immune response in BALBc mice 
(127,128). 
3.5.4 SAG_1386 
SAG_1386 is a small LysM domain containing protein. Our MetaV results revealed that 
LysM (Lysin Motif) domain is one of the most recurring Pfam domain within the protective 
antigens: P60 from L. monocytogenes, intimin from E. coli , Ebps from S. aureus  etc. 
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Bacteria retain certain proteins at their cell envelopes by attaching them in a non-covalent 
manner to peptidoglycan, using specific protein domains, such as the prominent LysM 
domain. LysM containing proteins are composed of not only truly secreted proteins, but also 
(outer-) membrane proteins, lipoproteins or proteins bound to the cell wall in a (non-)covalent 
manner. The motif typically ranges in length from 44 to 65 amino acid residues and binds to 
various types of peptidoglycan and chitin, most likely recognizing the N-acetylglucosamine 
moiety (129).  
3.6 The MetaV approach is able to catch distantly related protective antigens  
Figure 13 reports the domain organization of the 4 newly identified protective antigens, 
together with the corresponding %ID calculated from the primary sequence alignment to other 
known protective antigens belonging to the same MetaV class derived from other bacterial 
species, as reported in Table 7. This comparison clearly shows that sequence alignment would 
not be enough to catch the relationship between these distantly related proteins that share, on 
the other hand, the same domain composition and, in some cases, also the same domain 
organization at the whole protein architecture level.  In the present study, we show that they 
also shared conserved protective properties in different bacterial species, suggesting that these 
proteins can be involved in basic mechanisms of bacterial pathogenesis common to distant 
human pathogens (look at SAG_1333 functional characterization). 
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                                              (A)                                                               (B) 
 
Figure 13. Schematic  representation of domain architectures of the four new protective 
antigens identified in this study (A) and of other known protective antigens belonging to 
the same MetaV class derived from other bacterial species (B). Locations of domains in 
panels A and B are according to Pfam and SMART databases. Domains are drawn to 
approximate scale. 
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3.7 MetaVaccinology as a Basic Science Tool for GBS 
3.7.1 Expression Analysis of New Protective Antigens on GBS Surfome 
In order to prove expression of these four new protective antigens on the surface compartment 
of GBS, we used the surface digestion method as described previously (38, 40). Surface 
digestion is a new procedure that allows the rapid and selective identification of bacterial 
surface-exposed proteins, the pool of proteins which are entirely or partially exposed on the 
surface of the bacteria. The method uses proteolytic enzymes (trypsin and proteinase K) to 
‘shave’ the bacterial surface and the peptides generated are separated from the whole cells and 
identified by mass spectrometry.   
8 different GBS strains with a complete genome sequence, which represent the most 
important disease-causing serotypes: Ia (515 and A909), Ib (H36B), II (18RS21), III (COH1 
and NEM316), and V (2603 and CJB111) were used for these analyses. Very briefly, the 
exponentially growing live bacterial cells were collected and treated with trypsin and/or PK, 
in order to shave the bacterial surface and generate peptides from protein domains exposed on 
the extracellular space. Peptides released into the supernatant were analyzed by 
nanoLC/MS/MS followed by database search against the whole GBS proteomes.  
The surface proteome of the analyzed GBS strains consisted of 47 proteins, most of them 
(>90%) in silico predicted as extracellular or surface-associated. Table 11 shows the 
identified number of peptides corresponding to the protective antigens. This result indicates 
that SAG_1333, SAG_0954, SAG_0907 and SAG_1386 are expressed on the surface and 
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readily accessible to extracellular protease action and thus exposed on S.aureus surface, 
where it is expected to be accessible to circulating antibodies as well. 
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3.7.2 SAG_1333 Functional Characterization: An Immune Evasion Protein? 
The protectivity of 5’nucleotidases were previously shown against H. influenzae and Group A 
Streptococcus. In the case of GBS, the 5'-nucleotidase family protein was identified as an 
immunoreactive extracellular protein (131) and very interestingly, its transcription was 8.1 
fold upregulated in human amniotic fluid (132). This is very significant since the neonatal 
GBS infection can result from fetal aspiration or ingestion of the infected amniotic fluid. Very 
recently, Schneewind et al. (2010) reported that 5’nucleotidase of S. aureus (adsA) is a 
critical virulence factor which the synthesis of adenosine in blood, escape from phagocytic 
clearance, and subsequent formation of organ abscesses are all dependent on. Moreover, the 
AdsA homologue of Bacillus anthracis enabled escape from phagocytic clearance thus they 
suggest the bacterial pathogens may exploit the immunomodulatory characteristic of 
adenosine to escape host immune responses (133). All these 5’nucleotidases from different 
pathogens have the same domain organization but low sequence identity that is very well-
matched with our MetaV hypothesis (Figure 14).  
The functional characterization studies on the secreted ATP utilizing enzymes of Vibrio 
cholerae and Burkholderia cepacia showed that 5’-nucleotidases play an important role in 
allowing pathogens to evade host defence (134, 135) It is also reported that the growth 
medium of V. cholerae fractions, harboring 5’ nucleotidase, Ndk, and presumably other ATP-
utilizing enzymes are causing enhanced macrophage and mast cell death by activating P2Z 
receptors. (134) Additionally, the level of secretion of the 5-nucleotidase B. cepacia was 
reported as lower in the environmental strains than in the clinical strains that show the 
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importance of the protein for virulence (135).   
Vasu Punj et. al stated that 5'-nucleotidase of V. cholerae dephosphorylates the 5'-terminal 
phosphates from nucleoside phosphates such as AMP, ADP, or ATP and different ionic forms 
of ATP and adenine nucleotides have differential agonistic activities towards P2Z receptor 
activation of macrophages (136, 137). Secretion of 5'-nucleotidase by V. cholerae VB1 cells 
that can generate adenosine, AMP, and ADP from ATP can modulate macrophage cell death 
through multiple mechanisms. Indeed, it has been reported that a continuous generation of 
adenosine within the human epidermoid carcinoma cells can lead to an intracellular 
nucleotide imbalance with pyrimidine starvation, triggering suicidal processes ending up in 
apoptosis of the cells (138).  In a recent study on T. spiralis larvae, it has shown that 5-
nucleotidase enzyme converts substrate specifically AMP to adenosine. (139) 
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Figure 14. The protein architectures of different 5’ nucleotidase proteins from different 
pathogens.  
 
Adenosine is a purine nucleoside, which is produced also inside the human body under 
metabolic stress like hypoxic conditions, acute or chronic inflammatory tissue insults. The 
synthesis of adenosine involves the catabolism of adenine nucleotides (ATP, ADP and AMP) 
by the action of extracellular ectonucleotidases i.e. CD39 or nucleoside triphosphate 
dephosphorylase (NTPD) and CD73 or 5′-ectonucleotidase.  Once adenosine is released in the 
extracellular environment, it binds to different types of adenosine (i.e. adenosine A1, A2A, 
A2B and A3 receptors) receptors expressed on various innate immune cells [Neutrophils, 
macrophages, mast cells, dendritic cells and natural killer cells]. Thus, depending on the type 
of adenosine receptor to which it binds, adenosine modulates innate immune response 
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during various inflammatory conditions [i.e. chronic (cancer, asthma) as well as acute (sepsis, 
acute lung injury) inflammatory diseases]. Besides expressing various other receptors, 
macrophages also express all the four types of adenosine receptors (i.e. adenosine A1, A2A, 
A2B and A3 receptors) (140). 
Exogenous adenosine prevents differentiation of monocyte into macrophages and blocks 
monocyte development at a stage, which resembles phenotypically to dendritic cells. The 
binding of adenosine to adenosine A1 receptors on monocytes promotes transformation of 
these cells into multinucleated giant cells but binding of adenosine to adenosine A2 receptors 
prevents generation of these giant cells. Besides affecting the maturation of monocytes into 
macrophages, adenosine also suppresses the phagocytic function of macrophages by binding 
to the adenosine A2 receptors expressed on monocytes or macrophages (140). 
In the view of all these knowledge about 5’nucleotidases and adenosine, we constructed a 
hypothesis about the function of SAG_1333 and decided to test it. The hypothesis was 
assuming the transformation of AMP to adenosine by SAG_1333 enzymatic activity and the 
direct or indirect effects of adenosine on macrophages. 
In order to test this, we used xCELLigence System from Roche that monitors cellular events 
in real time without the incorporation. The impedance measurement provides quantitative 
information about the biological status of the cells, including cell number, viability, and 
morphology.  
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The results of our experiments show that SAG_1333 protein or AMP alone has no toxic effect 
on macrophages. On the other hand, in the presence of AMP (5mM), SAG_1333 is toxic for 
macrophages and causing significant cell death (Figure 15). The killing effect of SAG_1333 
is slower than the pore forming toxin (positive control of the experiment); this data is 
overlapping with our data since the effect is driven by a product of an enzymatic reaction. 
Very interestingly, further experiments on epithelial cells showed that AMP+SAG_1333 have 
no toxic effect on these cells. This observation is quite remarkable that the effect could be 
immune cells or macrophages specific.  in addition, the N-terminal of the SAG_1333 
(Metallophos domain) has also no effect on the macrophages either presence or absence of the 
AMP that shows the function of the SAG_1333 is dependent to C terminal (PF02872, 
5_nucleotid_C). The function of 5_nucleotid_C domain is predicted to catalyze the hydrolysis 
of phosphate and this is matching with the hypothesized function of SAG_1333 that is 
converting AMP to adenosine and the phenotype observed for macrophages is a consequence 
of this adenosine production.  
Figure 15I shows the effect of SAG_1333 on raw cells. It is observed that in the 5th hour after 
the addition of SAG_1333+AMP, the number of the macrophages starts to reduce while AMP 
and PBS alone has no effect. Figure 15II shows the results of the experiment based on 
carcinomic human alveolar basal epithelial cells (A549) and no effect observed. In the third 
experiment we used N-terminal of SAG_1333 and we did not observe any toxic effect on raw 
cells (Figure 15III). 
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Figure 15: xCELLigence System is used to monitor the effect of SAG_1333, 
SAG_1333+AMP, AMP alone and the controls on raw cells (I-first,III-third) and epithelial 
cells (II-second). Every color corresponds to a component added to cells and the figures show 
the effect on the cell numbers by time.  The dashed line shows the boundary of the “negative 
controls”.
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3.7.3 Discussion on the SAG_1333 function  
3.7.3.1 Why Adenosine is killing the Macrophages? A speculation: effect of Nitrix oxide? 
The question about the mechanism of adenosine action on macrophages remains unanswered 
but there are some data in the literature that we could speculate on. It is shown that adenosine 
and its receptor agonists enhanced the production of nitric oxide (NO) in lipopolysaccharide 
(LPS)-treated RAW 264.7 cells. The results of this study indicate that the enhancement effects 
of adenosine on NO production in macrophages could be mediated by the extracellular 
adenosine receptors as well as the downstream metabolites of adenosine. The ubiquitous free 
radical, NO plays an important role in many biological processes including the regulation of 
the inflammatory response. High concentrations of either exogenous or endogenous inductible 
nitric oxide synthase (iNOS) derived NO have been shown to induce apoptosis in murine 
macrophage cell lines. However, despite the apparent reduced capacity of human 
macrophages in comparison to murine macrophages, to generate iNOS derived NO, human 
macrophages do undergo apoptosis in response to exogenous NO (141). The causes of 
macrophage apoptosis in response to nitric oxide are known to be DNA damage and 
mitochondrial stress which up-regulate p53, release cytochrome c, and activate caspases 
(142). 
A study confirms the importance of NO for GBS mediated macrophage apoptosis.  GBS 
infection was studied in murine macrophage-like J774A.1 cells and gene expression was 
analyzed before apoptosis. Inhibition of iNOS gene expression by use of N(G)-monomethyl-
L-arginine (NMMA) inhibited apoptosis, whereas inhibition of TNF-alpha and IL-1 
biological activity did not. Macrophages from congenic iNOS-deficient mice were less 
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susceptible to apoptosis than were macrophages from C57BL/6 mice. These results show that 
NO is an important mediator of GBS-induced murine macrophage apoptosis but does not 
contribute to antimicrobial activity or cytotoxicity in human monocyte-derived macrophages 
(143). 
Moreover, Marriott HM et al. also reported similar results on pneumococcal-associated 
macrophage apoptosis. They showed that NO-mediated macrophage apoptosis during 
pneumococcal infection involves mitochondrial membrane permeabilization and in the 
presence of inducible nitric oxide synthase (iNOS) inhibition pneumococcal infection results 
in macrophage necrosis. The study provides the evidence of the at lower concentrations, NO 
contributes to pneumococcal killing; at higher concentrations it facilitates MMP 
(mitochondrial membrane permeabilization)-mediated apoptosis (144). These findings 
implicate NO as an important factor in macrophage apoptosis during GBS and pneumococcal 
infection.  
3.7.3.2 GBS and Macrophage Apoptosis 
The ability of pathogens to promote apoptosis may be important for the initiation of infection, 
bacterial survival, and escape from the host immune response. In fact, because apoptosis 
occurs without the release of cellular components, it does not usually lead to inflammation. 
Therefore, apoptosis may be advantageous for the pathogen because it might avoid the 
triggering and recruitment of non specific host defense mechanisms. Furthermore, 
macrophage death could also contribute to delaying or hindering the development of a 
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specific immune response.  
Fettucciari et al. demonstrated that serotype III GBS induces apoptosis in infected 
macrophages. Their investigation showed that down-regulation of β-hemolysin expression, by 
growth of GBS in glucose-supplemented media, inhibited macrophage apoptosis, which 
suggests that the surface-bound β-hemolysin of GBS is the bacterial factor responsible for 
stimulating apoptosis in infected macrophages. However, there has been no direct 
demonstration that GBS β-hemolysin plays a role in apoptosis of macrophages (145) 
In a following study, Ulett et al. investigated the role that β-hemolysin plays in nonopsonic 
phagocytosis, intracellular survival, and apoptosis in infected macrophages. They compared 
the effect of phagocytosis of a β-hemolysin–deficient isogenic mutant of serotype III GBS 
with that of the wild-type β-hemolytic parental strain and the ability of these strains to survive 
in macrophages and induce host-cell apoptosis. Growth conditions in which glucose levels 
were high were used to inhibit β-hemolysin expression in GBS strains, and the effect on the 
induction of macrophage cell death was assessed. The results of this study demonstrated that 
apoptosis in serotype III GBS–infected macrophages does not depend on β-hemolysin per se 
but on a factor coregulated with β-hemolysin by glucose (146). 
 
3.7.3.3 SAG_1333 may be an important factor for GBS mediated macrophage apoptosis 
All these references from literature combined to our experimental data shows that SAG_1333, 
the 5’nucleotidase protein of GBS, may be the unknown factor that is responsible from 
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GBS mediated macrophage apoptosis. One more encouraging data is coming from a recently 
published article that shows the PH regulation of SAG_1333 (147). The inverse ratio between 
PH and glucose is well known; the high glucose corresponds to lower PH in the medium.  
This result indirectly shows that SAG_1333 is regulated by glucose as the factor pointed out 
by Ulett GC et al.  
We need further microscopic experiments in order to understand the effect of the SAG_1333 
on the macrophages. Additional experiments with different cell types could help to show the 
specificity of the effect to macrophages and or immune cells.  
 
 
Figure 16. Immunoblot analysis on cell extracts of GBS grown at pH 7.0 or pH 5.5. 
Bacterial extracts were fractionated by SDS-PAGE, transferred to nitrocellulose, and the blots 
developed with mouse antisera specific for SAG1333 At pH 5.5 a reduction of SAG_1333 
was observed (147) 
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3.8 LysM Domain and Protectivity 
LysM domain is one of the most recurring MetaV domains within protective antigens. Figure 
18 shows the proteins architectures of LysM domain containing protective antigens; intimin 
(eae) from E. coli, surface immunogenic protein from GBS, elastin binding protein from S. 
aureus, P60 from L. monocytogenes and lastly spr0096 from S. pneumoniae. The sequence 
identities within these protective antigens are 3-30 % and it is impossible to detect any 
homology by looking primary sequence. On the other hand, all these protective antigens carry 
a LysM domain. The 2 protective antigens that are identified during present study, SAG_1386 
and SAOUHSC_00427 are also LysM domain containing proteins.  
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Figure 17: Protein architecture of different LysM domain containing protective antigens 
from different bacterial pathogens.  
 
3.9 MetaVaccinology (MetaV) applied to Staphylococcus aureus 
The results reported above for GBS are the first proof of the concept for MetaVaccinology as 
a new in-silico vaccine discovery tool.  In order to show the efficiency of MetaVaccinology as 
a prediction instrument, we decided to repeat the experiments for S. aureus. The available 
complete genome of S. aureus strain NCTC 8325 is used, the corresponding protein sequence 
information from the UniProt knowledgebase was scanned for the occurrence of the MetaV 
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molecular features. PROSPERO were used to detect internal repeat containing proteins. 9 of 
all MetaV candidates are selected to be tested in animal model that are shown below (Table 
12).  
Table 12. The MetaV antigens of S.aureus selected to be tested in animal model.  
No ORF Annotation Pfam Domain  
1 SAOUHSC_00400 conserved hypothetical protein No Pfam domain  
2 SAOUHSC_00256 Putative uncharacterized protein   PF05257. CHAP 
3 SAOUHSC_00994 bifunctional autolysin precursor (Atl) PF01510. Amidase_2   
PF01832. Glucosaminidase 
4 SAOUHSC_00671   Secretory antigen SsaA-like protein  PF05257. CHAP 
PF01476. LysM 
5 SAOUHSC_00427 N-acetylmuramoyl-L-alanine amidase 
sle1 
 PF05257. CHAP 
PF01476. LysM 
6 SAOUHSC_01949 Intracellular serine protease   PF00082. Peptidase_S8 
7 SAOUHSC_00994 Bifunctional autolysin PF01510. Amidase_2.  
PF01832. Glucosaminidase 
8 SAOUHSC_02576 Secretory antigen SsaA PF05257. CHAP 
9 SAOUHSC_02979 Putative uncharacterized protein PF05257. CHAP 
PF01832. Glucosaminidase.  
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3.9.1 Identification of 5 new protective antigens against Staphylococcus aureus 
Among the MetaV candidates, we decided to test 9 of them in animal model. In order to 
assess their efficacy in term of elicited protective immunity against natural infection, we 
performed in vivo experiments in mouse model using Newman as challenge strain. Survival of 
mice were monitored for fifteen days and protection values were calculated as as [(% 
deadControl - % deadVaccine) / % deadControl ] x100. Among the nine antigens tested in the animal 
model, five were able to induce a significant level of protection as compared to the control 
group i.e. putative uncharacterized protein SAOUHSC_00256 (% 57), conserved hypothetical 
protein SAOUHSC_00400 ((% 49) for SA-01 schema and N-acetylmuramoyl-L-alanine 
amidase sle1, SAOUHSC_00427 (% 90), intracellular serine protease SAOUHSC_01949 (% 
60), putative uncharacterized protein SAOUHSC_02979 (% 81) for SA-02 schema (Table 
13). 
3 of 5 newly identified protective antigens; SAOUHSC_00256 and SAOUHSC_02979 are 
carrying a CHAP domain as PcsB from S. pneumoniae while SAOUHSC_00427 is carrying 
both LysM and CHAP domains. SAOUHSC_01949 has Peptidase_S8 domain as C5a 
peptidases from S. agalactiae, Spy0416 from S. pyogenes ,prtA from S. pneumonia  
NMB1969 from N. meningitidis . SAOUHSC_00400 is a S. aureus specific protein that does 
not carry any defined Pfam domains. 
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Table 13. Protective activity of the selected S. aureus proteins compared with Alum as 
negative control. Protection values were calculated as as [(% deadControl - % deadVaccine) / 
% deadControl ] x100. 
(SA-01)                      
Name of the protein 
Survival  Survival % Protective 
Efficacy 
n° animals 
SAOUHSC_00256 10 of 16 63 57 
SAOUHSC_00671   1 of 16 6 0 
SAOUHSC_00994  6 of 16 38 29 
SAOUHSC_00400   9 of 16 56 49 
Alum 2 of 16 13 * 
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(SA-02)                      
Name of the protein 
Survival  Survival % Protective 
Efficacy 
n° animals 
SAOUHSC_00427 15 of 16 94 90 
SAOUHSC_01949 12 of 16 75 60 
SAOUHSC_02979 14 of 16 88 81 
SAOUHSC_02576 9 of 16 56 29 
Alum 6 of 16 38 * 
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Very recently, Holtfreter et. al published a  review of the current knowledge about antibody 
responses against S. aureus which challenges the adaptive immune system with abroad and 
highly variable antigen repertoire (148). They collected all the results of the different 
techniques to map the core and the variable S. aureus immuneproteomes, which aims to 
constitute the knowledge base for the design of effective anti-S.aureus vaccine compositions. 
All vaccination strategies against S. aureus rely on a central feature of adaptive immunity: 
immunological memory. The high susceptibility to S. aureus infection in patients with 
immunoglobulin deficiency and the wealth of escape mechanisms developed by S. aureus that 
allow it to interfere with antibody function are strong arguments in favor of an important role 
for adaptive immunity for this particular pathogen.  
2 of 5 protective antigens that are identified by MetaV approach (i) SAOUHSC_00256 
(staphyloxanthine biosynthesis protein, putative) and (ii) SAOUHSC_02979 (putative 
uncharacterized protein) are reported as immunogenic proteins only against sera collected 
from healthy individuals but not from carriers or patients. Moreover, SAOUHSC_00427 is 
reacted with sera both collected from healthy individuals and the patients. SAOUHSC_00400 
and SAOUHSC_01949 are not identified any of these studies (148) 
This knowledge is particularly interesting for vaccine design if the presence of immune 
response is really specific to healthy individuals. We could speculate that these antibodies are 
so protective that S. aureus can not colonize and/or infect these individuals who have 
antibodies against these antigens. 
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There is a need for functional characterization of the new protective antigens. Remarkably, 3 
protective antigens carry (cysteine, histidine-dependent amidohydrolases/peptidases) a CHAP 
domain that is often found in association with other domains that cleave peptidoglycan. 
Cleavage of peptidoglycan plays an important role in bacterial cell division, cell growth and 
cell lysis. A review on CHAP domains published by Sanger Institute revealed that several 
known peptidoglycan amidases fall into CHAP family which includes two different 
peptidoglycan cleavage activities: L-muramoyl-L-alanine amidase and D-alanyl-glycyl 
endopeptidase activity. The family includes the amidase portion of the bifunctional 
glutathionylspermidine synthase/amidase enzyme from bacteria and pathogenic 
trypanosomes. The large number of multifunctional hydrolases suggests that they might act in 
a cooperative manner to cleave specialized substrates (149). A very recent systematic analysis 
of CHAP domain in 12 S. aureus genomes and 44 staphylococcal phage genomes revealed 
that there are 234 putative CHAP-containing proteins for S. aureus (150). 
SAOUHSC_00427 (N-acetylmuramoyl-L-alanine amidase sle1) is the only functionally 
characterized protein within our new candidates. Kajimura et al. reported that this 
peptidoglycan hydrolase preferentially cleaved N-acetylmuramyl-L-Ala bonds in dimeric 
cross-bridges that interlink the two murein strands in the peptidoglycan. An insertion 
mutation of sle1 impaired cell separation and induced S. aureus to form clusters suggesting 
Sle1 is involved in cell separation of S. aureus. The Sle1 mutant revealed a significant 
decrease in pathogenesis using an acute infection mouse model. Atl (SAOUHSC_00994) is 
the major autolysin of S. aureus, which has been implicated in cell separation of S. aureus. 
Generation of an atl/sle1 double mutant revealed that the mutant cell separation was 
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heavily impaired suggesting that S. aureus uses two peptidoglycan hydrolases, Atl and Sle1, 
for cell separation. Unlike Atl, Sle1 was not directly involved in autolysis of S. Aureus (151). 
On the other hand, our results show that although both of these proteins have a similar and 
essential function for cell seperation, Atl is not a protective antigen against S. aureus (SA-01) 
3.10 Comparison of MetaV with Other Vaccine Discovery Tools 
3.10.1 Reverse Vaccinology and MetaV 
Reverse Vaccinology and other genomics-based vaccine discovery tools commonly rely on 
the prediction of potential cell surface/secreted proteins for the identification of new vaccine 
candidates and predicted subcellular localization is available for almost all the known 
bacterial proteins through dedicated or general databases, e.g. the PSORTdb 
(http://db.psort.org/) and UniProtKB (http://www.uniprot.org/).  Specific algorithms suitable 
for the in silico identification of novel surface-exposed and, thus, antibody accessible proteins 
mediating a protective response are used, mostly the signal peptide.    
In order to understand the efficacy of signal peptide (SP) prediction, we analyzed the 
presence/absence of SP within all protective antigens that are shown in Table 6. A specific SP 
could not be detected for 39 out of 91 protective antigens and moreover final localization of 
23 proteins are predicted as, cytoplasmic membrane for 5, unknown for 16 and periplasmic 
for 2 by PsortB. These 39 antigens without a signal peptide could be classified according to 
their function/structure; the flagellin proteins that are within the best vaccine candidates for 
many pathogens were totally out of the detection. As a second group, the main Clostridium 
toxins; tetanus toxin from C. tetani, botulinum toxin of C. botulinum, toxin A/B from C. 
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difficile, the pore forming toxins, hemolysin of E.coli, Listeriolysin O of L. monocytogenes  
and Ply of S. pneumoniae do not contain a signal peptide. In addition to those, SdrC, SdrD, 
SdrE proteins of  S. aureus and and LysM domain containing proteins intimin from E. coli, 
Ebps from S. aureus and SAG_1386 from GBS do not have a predictable SP (Table 14) 
This is particularly meaningful, since there is an increasing awareness that secretion pathways 
in bacteria are far more complex than expected, there are seven different secretion systems 
identified in Gram-negative and six others for Gram-positive bacteria, yet. The identification 
of WXG100 domain containing ESAT-6 (esxA) and CFP-10 (esxB) proteins that are the main 
candidates for an effective subunit vaccine against M. tuberculosis caused the recent 
discovery of a new secretory pathway for Gram + bacteria. Both of these proteins lack a 
distinguishable Sec-signal sequence, which suggests the existence of a specialized secretion 
pathway. Several independent studies have demonstrated that the genes that surround the 
ESAT6- and CFP10-encoding genes are involved in the production of such a specialized 
secretion system; type VII secretion (152).  
The MetaV approach has the advantage of being independent from the prediction of potential 
cell surface/secreted proteins for the identification of possible new vaccine candidates, 
because it relies on the occurrence of specific molecular features, either functional or 
structural, over the protein whole length, regardless to the presence of a classical signal 
peptide for secretion.  
The Reverse Vaccinology approach successfully applied to GBS. In total, 589 proteins are 
selected as surface exposed proteins and among thoses 312 were exp
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recombinant proteins, purified and tested for protection against GBS. Four proteins were 
found to elicit protective immunity in an animal model. This is a very comprehensive 
screening of the possible candidates but labor intensive and expensive to be performed. On 
the other hand, MetaV, by using the extraction of the knowledge of RV approach, reduces the 
number of proteins to be tested and theoretically enriches the number of protective antigens 
within this list.  
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3.10.2 MetaVaccinology and ANTIGENome technology 
The expression of vaccine candidates during natural infection in humans is compulsory for 
subunit vaccines. In order to assess the capability of MetaVaccinology to predict 
immunogenic proteins that are recognized by human humoral immune system, we used the 
results of recently published article of Meinke et al (2010). Very briefly, ANTIGENome 
technology was used to identify new vaccine candidates by using a broad range of sera and 
cervical secretions obtained from either healthy or GBS colonized women against genomic 
surface display libraries. They identified 35 most frequently selected immunogenic proteins 
within 167 others (153).  
We decided to analyze these 35 most immunogenic proteins; regarding to their coincidence 
with our MetaV selection. The protein architecture of all proteins are analyzed and the results 
show that among all immunogenic proteins; 27 (% 77) are covered by MetaV approach: (i) 9 
proteins carry MetaV Pfam domains and (ii) 18 proteins are Streptococci-specific. The 8 
proteins that are out of MetaV list are mostly cytoplasmic enzymes like ThiI/ Probable tRNA 
sulfurtransferase or NH3-dependent NAD+ synthetase. Table 15 shows the Meta analysis, 
annotation and domain composition of the immunogenic proteins identified by 
ANTIGENome.  Two of four protective antigens that we identified by MetaV approach; 
gbs1403 (SAG_1333) and gbs0918 (SAG_0907) are present in the immunogenic proteins 
described in this paper, on the other hand SAG_1386 and SAG_0954 are not.  
The same group used ANTIGENome technology in order to have a comprehensive in vivo 
antigenic profile of Staphylococcus aureus N315 strain. A total of 23 antigenic proteins 
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were reported as immunogenic proteins frequently identified by bacterial surface display, 
according to their reactivity with individual sera from patients and healthy individual (27). 
Among the nine MetaVaccinology antigens tested in the animal model, five were able to 
induce a significant level of protection as compared to the control group; i.e. 
SAOUHSC_00256 (SA0270), SAOUHSC_00400 (SA0394) SAOUHSC_00427 (SA0423),  
SAOUHSC_01949 (no homolog for S. aureus N315 strain) and SAOUHSC_02979 (SA2437). 
None of these protective antigens are identified by the ANTIGENome technology as 
immunogenic, thus could be never identified as vaccine candidates by this approach. 
As already mentioned before Silva Holtfreter et. al published a  review concerning the current 
knowledge about antibody responses against S. aureus (148). 2 of 5 protective antigens that 
are identified by MetaV approach (i) SAOUHSC_00256 (staphyloxanthine biosynthesis 
protein, putative) and (ii) SAOUHSC_02979 (putative uncharacterized protein) are reported 
as immunogenic proteins only against sera collected from healthy individuals but not from 
carriers or patients. Moreover, SAOUHSC_00427 is reacted with sera both collected from 
healthy individuals and the patients. SAOUHSC_00400 and SAOUHSC_01949 are not 
identified any of these studies.  
All these results prove the fact that MetaV could also predict the in vivo immunogenic 
antigens that give a significant advantage to any vaccine discovery tool. Moreover, the 
protective antigens identified by MetaV can not be identified by ANTIGENome.  
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3.10.3 MetaVaccinology and Surfome analysis  
The first use and description of surfome the analysis as a vaccine discovery tool was by 
Rodriguez-Ortega et al. A relevant result of this work was the demonstration that 
comprehensive characterization of surface-exposed proteins can lead to new vaccine 
candidate discovery. Among the 14 identified surface proteins tested, one protein, Spy0416, 
conferred high protection levels (38). Secondly, this approach was used in order to analyze 
the surfome of Group B Streptococcus, COH1 strain and to identify new vaccine candidates.  
When applied to the Group B Streptococcus COH1 strain, 43 surface-associated proteins were 
identified, including all the protective antigens described in the literature as well as a new 
protective antigen, the cell wall-anchored protein SAN_1485 belonging to the serine-rich 
repeat protein family (40).  
Of those two new protective antigens identified by surface digestion, Spy0416 is composed of 
DUF1034, PA (PF00082), Peptidase_S8 (PF00082) YSIRK_signal (PF04650) domains and 
SAN_1485 is composed of a SdrG_C_C (PF10425) domain.  Peptidase_S8 and SdrG_C_C 
are two MetaV core Pfam domains that are identified in 5 (both Gram -/+) and 2 different 
pathogens respectively (table 6). Both of these proteins are also the potential MetaV 
candidates because of their domain organization. In contrary, the protective antigens 
identified by our study are not the potential surfome analysis candidates.  Surface digestion 
methods uses the obtained peptide numbers as a selection criteria of potential vaccine 
candidates since it is assumed that surface exposition correlates with the number of peptides 
obtained. If we had used this criteria to select our proteins, by using our surfome analysis 
results, SAG_0954 (1 peptide), SAG_0907 (2 peptides) and SAG_1386 (1 peptide) would 
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never been selected (table 16).  Moreover, SAG_1333 (the most protective of four antigens 
against GBS) could not be identified on the surfome of COH1 in our previous study (40); 
although the protein was reported to be highly immunogenic by using human sera that shows 
its in vivo expression (153).  
We could also compare MetaV and surfome analysis for S. aureus. There is a very recently 
published article on S. aureus surfome thatVentura C. L. et al. analyzed the cell surface 
proteome of USA300 strain LAC. A total of 113 identified proteins were associated with the 
surface of USA300 during the late-exponential phase of growth in vitro (154). Even though, 
the work is called surfome analysis, a high percentage of the proteins are cytoplasmic that 
causes question marks about the quality of the surfome analysis.  We compared the protective 
antigens that were identified by using MetaV in order to understand if they were detectable by 
this surfome analysis.  Of those 5 protective antigens only N-acetylmuramoyl-L-alanine 
amidase sle1 SAOUHSC_00427 (SAUSA300_0438) was identified on the surface of 
USA_300 strain while SAOUHSC_00256 (SAUSA300_0651), SAOUHSC_00400 
(SAUSA300_0408) SAOUHSC_00427 (SAUSA300_0438), SAOUHSC_01949 
(SAUSA300_1763), SAOUHSC_02979 (SAUSA300_2579) could not. 
The protective antigens must either well expressed on the surface or secreted ones. So why 
could not we show this well expression by using surfome analysis for our protective antigens? 
This could be due to diversity between in vivo and in vitro conditions that causes a significant 
difference on the expression of the proteins. Unlike the genome, proteome is a dynamic 
composition and the expression profile is directly effected by the external conditions. 
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Likewise, the in vivo proteome of a pathogen is also dynamic that could adapt immediately to 
new external conditions.  
GBS is a major neonatal pathogen that is able to adapt to a variety of host environments, 
including both rectal and vaginal maternal carriage, growth in amniotic fluid and at various 
neonatal body sites. Transcriptomics studies of GBS could let us to explain its ability to adapt 
different environmental conditions. Moreover, these studies could help us to explain and 
understand, why we could not identify all these protective antigens as well exposed proteins 
on the surface of GBS by using in vitro conditions. 
3.10.4 Transcriptomics: Another Genomics Tool to Understand Pathogenicity of GBS 
James Musser and his colleagues published three different articles about the GBS 
transcriptome. In the first study, to enhance understanding of how GBS adapts during 
invasive infection, they performed a whole-genome transcriptome analysis of GBS after 
incubation with whole human blood. Global changes occurred in the GBS transcriptome 
rapidly in response to blood contact following shift from growth in a rich laboratory medium. 
The transcripts of relatively few proven virulence genes were up-regulated during the first 90 
minutes. However, a key discovery was that genes encoding proteins involved in interaction 
with the host coagulation/fibrinolysis system and bacterial-host interactions were rapidly up-
regulated. Extensive transcript changes also occurred for genes involved in carbohydrate 
metabolism, including multi-functional proteins and regulators putatively involved in 
pathogenesis. Additionally, they discovered that an incubation temperature closer to that 
occurring in patients with severe infection and high fever (40 degrees C) induced 
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additional differences in the GBS transcriptome relative to normal body temperature (37 
degrees C) (155). 
In a second study, to understand the response to temperatures encountered in the various 
hosts, they conducted a whole genome transcriptome analysis for organisms grown at 30 
degrees C and 40 degrees C. They identified extensive transcriptome remodeling at various 
stages of growth, especially in the stationary phase (significant transcript changes occurred for 
25% of the genes). A large proportion of genes involved in metabolism were up-regulated at 
30 degrees oC in stationary phase. Conversely, genes up-regulated at 40 degrees oC relative to 
30 degrees C include those encoding virulence factors such as hemolysins and extracellular 
secreted proteins with LPXTG motifs. Over-expression of hemolysins was linked to larger 
zones of hemolysis and enhanced hemolytic activity at 40 degrees oC. A key theme identified 
by this study was that genes involved in purine metabolism and iron acquisition were 
significantly up-regulated at 40 degrees C (156). 
Thirdly, they used amniotic fluid to grow bacteria and characterized the transcriptome of GBS 
grown in human amniotic fluid (AF) comparing it with the transcriptome in rich laboratory 
medium. They discovered that GBS significantly remodels its transcriptome in response to 
exposure to human amniotic fluid. GBS grew rapidly in human AF and did not exhibit a 
global stress response. The majority of changes in GBS transcripts in AF compared to THY 
medium were related to genes mediating metabolism of amino acids, carbohydrates, and 
nucleotides. The majority of the observed changes in transcripts affects genes involved in 
basic bacterial metabolism and is connected to AF composition and nutritional requirements 
of the bacterium. Importantly, the response to growth in human AF included significant 
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changes in transcripts of multiple virulence genes such as adhesins, capsule, and hemolysin 
and IL-8 proteinase what might have consequences for the outcome of host-pathogen 
interactions (157). 
Lastly, Soriani et al. performed a comparative global gene expression analysis of GBS at 
acidic and neutral pHs. They found that the transcription of 317 genes was increased at pH 5.5 
relative to that at pH 7.0, while 61 genes were downregulated. The global response to acid 
stress included the differential expression of genes involved in transport, metabolism, stress 
response, and virulence. Known vaccine candidates, such as BibA and pilus components, 
were also regulated by pH.  These results imply that the translocation of GBS from the acidic 
milieu of the vagina to the neutral pH of the neonatal lung signals the up-regulation of GBS 
virulence factors and conversion from a colonizing to an invasive phenotype (147).  
All these articles show the fascinating ability and harmony of a pathogen to adapt different 
conditions by immediately shifting its expression profile. It is difficult to observe all these 
changes on the surfome by using limited in vitro conditions. Moreover one of the most 
significant outcomes of these studies concerning our results is about the expression of 5’ 
nucleotidase SAG1333 (gbs1403). It was 8.1 times up-regulated in amniotic fluid that shows 
the importance of this antigen in amniotic fluid, just before transfering to lungs of the neonate 
(159). Additionally, at pH 5.5 a significant reduction was observed that could be interpreted 
as the down-regulation of the protein while colonizing on the vagina (137).  
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4. CONCLUSIONS 
A comprehensive list of bacterial antigens described as potential vaccine candidates, based on 
in vivo animal models and/or on in vitro assays, was created from literature data and from on 
line available databases, e.g. the VIOLIN web site. 115 different protective antigens from 23 
bacterial pathogens, 13 gram negative  and 10 are gram positive, were considered for this 
process. 
A systematic analysis of these antigens was carried out at the molecular level, using different 
bioinformatics tools and looking for conserved molecular features. The results of this analysis 
revealed that protective antigens from different species rarely show a conserved protein 
architecture over the whole sequence and a significant sequence similarity (>50% ID).   
On the other hand, the results of this meta-analysis showed that protective antigens have 
recurring functional and/or structural units, which were in most cases associated to either 
specific domain from the Pfam databases or to a conserved protein architecture organized in a 
variable number of multiple internal repeats. The rest of the protective antigens not showing 
these properties were found to be either species-specific or genus-specific ORFs by genomic 
analysis  
We used these features as “vaccine signatures” in a predictive selection process of new 
protective antigens in other species, and in the present study, we show the results obtained 
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from the application to GBS and S. aureus. 
Among the nine antigens tested in the animal model against GBS, four were able to induce a 
significant level of protection as compared to the control group, i.e. the 5’ nucleotidase 
SAG1333, the histidine-triad protein SAG0907, the Bmp protein SAG0954 and the LysM 
domain-containing protein SAG1386.\ 
Among the nine antigens tested in the animal model against S. aureus, five were able to 
induce a significant level of protection as compared to the control group i.e. putative 
uncharacterized protein SAOUHSC_00256, conserved hypothetical protein 
SAOUHSC_00400, N-acetylmuramoyl-L-alanine amidase sle1 SAOUHSC_00427, 
intracellular serine protease SAOUHSC_0194 and putative uncharacterized protein 
SAOUHSC_02979. 
In order to check the expression of the MetaVaccinology identified protective antigens on the 
surface compartment of GBS, we used surfome analysis for 8 different strains of GBS. The 
expression of protective antigens on the surface compartment of GBS was confirmed by this 
way.  
Our results indicate that the MetaVaccinology selection process is a powerful discovery tool 
in vaccine research and we expect this approach can be of particular interest for projects in the 
pre-discovery phase, allowing the fast identification of protective antigens with conserved 
“vaccine signatures”. 
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The new identified proteins share common functional/structural domains with antigens proved 
to be protective and relevant to the pathogenesis of other important pathogens, i.e. 
Haemophilus influenzae, Staphylococcus aureus and Streptococcus pneumoniae. For this 
reason, the MetaVaccinology approach can also be exploited as a basic science tool, as it 
provides insights about possible common mechanisms of pathogenesis in different bacterial 
species. 
Related to this last point, the role of 5’nucleotidase in immune evasion for GBS was 
investigated and our study shows that SAG_1333 has a toxic effect on the macrophages in the 
presence of AMP.  
The identification of common mechanisms of pathogenesis for such a different range of 
pathogens, including Gram positive and Gram negatives, can also open the way to the design 
of new antimicrobials and other therapeutic treatments. 
As a final comment, MetaVaccinology could be exploited to make vaccines against any 
bacterial pathogen, including the most dangerous ones i.e Mycobacterium tuberculosis. On 
the other, we think that MetaV could be also applied for the parasites i.e the Plasmodium 
falciparum which is not a bacteria but a protozoan parasite causing malaria. 
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